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SUMMARY
The suddeness of the onset of anaesthetic induced 
malignant hyperpyrexia in apparently healthy subjects, and 
the high mortality rate associated with it, represent one 
of the most dramatic clinical events in modern medicine.
The aetiology of the syndrome appears to include the 
detailed molecular structure of skeletal muscle cell 
membranes and the mechanism of calcium release. Muscle 
from susceptible patients responds abnormally to a variety 
of drugs and physical stimuli in vitro. High calcium 
levels in the myoplasm provide a rational explanation for 
the clinical and biochemical changes which occur during an 
episode of malignant hyperpyrexia.
The study presented in this thesis was undertaken 
to find the most suitable drug treatment. Methods employed 
included in vitro pharmacologic models of malignant 
hyperpyrexia based on normal human muscle. Drugs suggested 
for its treatment were evaluated and compared by measuring 
muscle response to drug administration in vitro. Muscle 
response to the drugs not only suggests a new drug treatment 
regime, but also specific biochemical changes in muscle 
membranes. Models of malignant hyperpyrexia based on 
normal human muscle were used to test drug efficacy and 
were supported by an in vitro study using malignant 
hyperpyrexia muscle.
A possible lesion in the control of phospholipid
vii
fluidity in malignant hyperpyrexia membranes has been 
discussed and supported by some evidence. The proposed 
mechanism provides a rational basis for effects by local 
anaesthetics, calcium induced calcium release, general 
anaesthetics and the molecular action of dantrolene.
No drug suggested for the treatment of malignant 
hyperpyrexia has proved reliable. The overv/helming 
efficacy of dantrolene in suppressing and reversing the 
abnormal contractures in muscle from susceptible patients, 
suggests dantrolene is the most suitable drug for the 
treatment of malignant hyperpyrexia. The safety of 
dantrolene should prompt authorities to approve parenteral 
administration. It would appear that dantrolene is the 
only drug tested so far, that could increase the appalling 
survival rate in malignant hyperpyrexia.
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1SECTION I - PRELIMINARY OBSERVATIONS
A: Introduction
Malignant hyperpyrexia (hyperthermia) was first 
reported by Denborough and Lovell in 1960 as a potentially 
lethal, autosomal dominant syndrome of unknown aetiology.
The condition they described consisted of a fulminant crisis 
triggered by potent inhalational anaesthetic agents, the 
outstanding features of which were fever, tachycardia, 
tachypnoea and cyanosis. In the few intervening years much 
has been learned about this remarkable pharmacogenetic 
disturbance of skeletal muscle.
The clinical features of the syndrome gradually 
emerged from various case reports, and a comprehensive 
statistical review of eighty-nine cases was published in 
1970 by Britt and Kalow. A typical case consisted of a 
previously healthy patient, most often a young male, who was 
undergoing minor surgery. The first indication of anything 
unusual was often an abnormal reaction to succinylcholine. 
Enhanced fasciculations, a failure to relax or generalized 
muscular rigidity made intubation technically difficult to 
accomplish. Often a second dose of succinylcholine was 
unfortunately given in an attempt to overcome the muscular 
rigidity.
The next manifestation of the syndrome was variable, 
and included tachycardia, tachypnoea, hypotension, cyanosis 
and muscular rigidity. Hyperpyrexia was usually only
2discovered when the patient's condition was rapidly 
deteriorating. All reports emphasised the rapid progression 
of the condition and also the difficulty in lowering the body 
temperature, even after packing the patient in ice. The 
majority of cases were fatal, death usually occurring within 
a few hours of the onset of the syndrome. It is now known 
that all individuals who are susceptible to malignant 
hyperpyrexia have an underlying disease of muscle, which may 
by subclinical (Denborough, Ebeling, King and Zapf, 1970; 
Isaacs and Barlow, 1970; King, Denborough and Zapf, 1972).
The discovery of an experimental animal, the 
Landrace pig (Hall, Woolf, Bradley and Jolly, 1966; Harrison, 
Biebuyck, Terblanche, Dent, Hickman and Saunders, 1968), the 
Pietrain pig (see refs in Hall, Lucke and Lister, 1975) and 
the Poland China pig (Nelson, Jones, Venable and Kerr, 1972) 
which suffered from a syndrome under general anaesthesia that 
appeared clinically identical to malignant hyperpyrexia, 
greatly assisted in the documentation of biochemical changes.
Investigations on susceptible pigs have shown that 
biochemical changes precede the development of both muscular 
rigidity and fever. The first major change in blood chemistry 
is a massive increase in lactic acid and a concomitant drop 
in blood pH.
By 1974 evidence supporting a biochemical lesion in 
skeletal muscle was mounting. Anaesthetic-induced malignant 
hyperpyrexia appears to result from increased free calcium 
levels in the myoplasm of skeletal muscle cells (Kalow, Britt,
3Terreau and Haist, 1970; Moulds and Denborough, 1972; Nelson 
et al., 1972; Britt, Kalow, Gordon, Humphrey and Rewcastle, 
1973; Harrison, 1973a; Britt, 1974). The source of this 
calcium in many human subjects seems to be the sarcoplasmic 
reticulum. (International Symposium on Malignant Hyperthermia, 
1973; Britt et al., 1973; Harrison, 1973b; Moulds et al.,
1972). Calcium release can be induced in susceptible muscle 
in vitro by a pharmacologically heterogeneous group of agents 
and also physical stimuli (Moulds and Denborough, 1974a).
These effects are dependent upon extracellular calcium levels 
(Moulds et al., 1974; Nelson, Bedell and Jones, 1975), and 
are influenced by temperature (Nelson et al., 1975; Nelson, 
Austin and Denborough, unpublished observations, 1975).
Although these recent reports have added to our 
knowledge of the underlying cellular abnormality in malignant 
hyperpyrexia, associated advances in the treatment of this 
syndrome have been conspicuously absent (Hall et al., 1975). 
Apart from clinical approaches to the control of hyperpyrexia 
and acidosis, no specific drug therapy has proved reliable. 
Once the syndrome is established, it is often irreversible.
Thirty-six percent (36%) of survivors of malignant 
hyperpyrexia have had no specific drug therapy (Britt et al., 
1970). Reports of successful treatment of the syndrome by a 
specific drug should therefore be treated with caution. The 
British Medical Journal in 1968 and Harrison in 1971 pointed 
out the lack of rationality in drug treatments for malignant 
hyperpyrexia. Since 1971 and up until late 1975, there have 
been six therapeutic regimes which have been reported as
4successful. However, the mortality rate is still in the 
region of seventy percent (Clarke and Ellis, 1975). The use 
of procaine in the treatment of malignant hyperpyrexia was 
widely accepted as the best drug up until 1974. Numerous 
reports on its failure to control the syndrome began to 
appear and in 1975 there was extensive confusion in the 
literature as to its suitability in treatment regimes (Hall, 
Lucke and Lister, 1975). The lack of rationality in drug 
treatments that Harrison spoke of in 1971 was still present 
in 1975.
Hyperpyrexia may recur with repeated anaesthetics 
in susceptible patients, but the condition has also been 
encountered in patients who have previously undergone 
anaesthesia without apparent difficulty (Britt, 1974). The 
suddeness of the onset of the syndrome in apparently healthy 
patients and the high mortality rate associated with it, 
represent one of the most catastrophic clinical events in 
modern medicine. The need for drug therapy is clear. Simple 
cooling and correction of the acidosis, although extremely 
important in any treatment regime, do not guarantee survival 
(Clarke et al., 1975). The success of a particular 
therapeutic regime is measured by its action on in vitro 
muscle models or in vivo malignant hyperpyrexia pig reactions. 
Specific therapy has had varying degrees of success in the 
treatment of malignant hyperpyrexia in the Pietrain pig. 
Measures such as the administration of sodium bicarbonate, 
hyperventilation, fluid replacement and surface cooling are 
important, but in the established swine syndrome, additional 
therapy is necessary to inhibit the explosion of muscle
5metabolism (Hall et al., 1975).
Methodological differences in the conditions for in 
vitro muscle studies of malignant hyperpyrexia have already 
contributed to the confusion in this field. Reports that 
muscle from patients susceptible to malignant hyperpyrexia 
was sensitive to halothane in vitro (Ellis et al., 1972; 
Moulds and Denborough, 1972) were negated by other workers 
(Kalow et al., 1970). However, a simple difference in 
temperature of the muscle incubation chamber has now been 
shown to be the cause of the conflicting reports. It is 
widely accepted that if muscle from malignant hyperpyrexia 
susceptible patients is tested in vitro at 37°C, exposure to 
halothane will induce contracture.
The failure of different workers to use standardised 
in vitro muscle procedures and the use of many models for 
malignant hyperpyrexia based on muscle from rats, rabbits, 
frogs, humans and malignant hyperpyrexia susceptible pigs 
made a comparative evaluation of drug efficacy in treatment 
regimes impossible (Harrison, 1973a; Clarke et al., 1975; 
Moulds et al., 1974a).
The difficulty in obtaining malignant hyperpyrexia 
muscle from humans for in vitro drug tests necessitates the 
selection of a model to evaluate drug efficacy. The choice 
of the most suitable model is discussed in a later section.
The general plea in the literature by a number of 
workers for an effective drug to reverse an already
6established syndrome prompted the study presented in this 
thesis (Harrison, 1971; Hall and Lister, 1974). The study 
was designed to compare the relative efficacy of the major 
drugs suggested in antagonising calcium release from the 
sarcoplasmic reticulum. A model based on normal human 
skeletal muscle was selected, and the effects of procaine, 
procainamide, hydrocortisone, dexamethasone and dantrolene 
on isometric drug induced contracture were measured and 
compared. The relationship between the final release of 
calcium from sarcoplasmic reticulum and muscle contracture is 
well documented (Close, 1972; Britt, 1973; Cohen, 1975;
Murray and Weber, 1974) . The choice of the most suitable 
drug in treating malignant hyperpyrexia based on the normal 
model, was confirmed by testing drug efficacy in vitro on 
muscle from a patient susceptible to the syndrome.
The selection of the most suitable drug in the 
treatment of malignant hyperpyrexia does not imply that 
normal clinical procedures should be eliminated. At present 
the key to success in the management of acute crises is early 
cessation of all potent inhalational anaesthetics and all 
muscle relaxants. A comprehensive clinical treatment course 
is fully described by Britt (1974) and involves the use of 
sodium bicarbonate, furosemide, mannitol, glucose and insulin 
or potassium chloride, renal dialysis and external cooling or 
extracorporeal cooling if an expert cardio-vascular team is 
available.
Unfortunately such treatments are not sufficient to 
guarantee survival. The main aim of the present study was to
7find the most effective drug therapy in the hope of 
increasing the appalling survival rate in malignant 
hyperpyrexia.
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8B: Normal skeletal muscle
i) Role of calcium
The skeletal muscle cell is enclosed by an outer 
basement membrane and an inner sarcolemma (see figure 1). At 
intervals a nerve ending is folded inward to the interior of 
the muscle fibre. These involutions greatly increase the 
area of nerve and muscle surfaces in contact with each other. 
Compared to the extracellular fluid the level of calcium 
within the myoplasm is low. During relaxation the sarcolemma 
can serve as a storage compartment for calcium ions and they 
are actively extruded from the myoplasm to the extracellular 
fluid across the surface membrane. At periodic intervals the 
sarcolemma is invaginated to form structures called 
transverse tubules (figure 1).
The sarcoplasmic reticulum appears to be the main 
site of calcium storage. It is composed of longitudinal 
elements, lying parallel to the muscle fibre axis and ends 
in enlarged terminal cisternae. These sacs are separated 
from the transverse tubules by partially bridged gaps.
Usually each transverse tubule is associated with two 
terminal cisternae (figure 1). Lying below the transverse 
tubule are the Z lines to which contractile proteins called 
actin are attached at right angles. Thick filaments, 
composed almost entirely of myosin, are long rod-shaped 
molecules with two globular heads, and they lie parallel 
and in between the actin filaments. Troponin and tropomyosin 
make up the remaining two major proteins found in the 
contractile apparatus. A nerve impulse terminates at the
9sarcolemma membrane. The impulse flows down the sarcolemma 
membrane into the transverse tubule, and the excited state 
of the transverse tubule is then transferred to the 
sarcoplasmic reticulum. Calcium ions are thought to be 
important in this transfer process. The calcium ions 
released from the transverse tubule induce a large release 
of calcium from the sarcoplasmic reticulum. This calcium 
has several effects. Muscle metabolism in general is 
stimulated, via activation of the phosphorylase system of 
enzymes, and thus the rate of glycolysis is increased. The 
calcium signal is detected and acted on by troponin and 
tropomyosin, which are positioned along the actin strand and 
with it constitute the thin filament. The calcium ions 
bind to the troponin, which then modifies the position of 
the tropomyosin molecules so that the myosin heads can 
contact the actin molecules. The contact of these two 
components results in shortening of a muscle fibril and thus 
muscle contraction.
The process whereby the 'electrically' excited 
sarcolemma is coupled to calcium release from the sarcoplasmic 
reticulum is known as the excitation-contraction coupling 
mechanism.
Calcium, in vivo, is released from the sarcoplasmic 
reticulum following depolarisation of the sarcolemma 
membrane. An electrical stimulus applied to muscle in vitro 
causing depolarisation of the sarcolemma, results in muscle 
contraction. A variety of drugs can also induce contracture, 
with or without depolarisation of the sarcolemma membrane.
10
Thus potassium chloride if added to the buffer surrounding a 
piece of skeletal muscle in a high enough concentration can 
cause artificial depolarisation, and contraction occurs. 
Caffeine if added at an appropriate level may also induce 
contracture without depolarisation of the sarcolemma.
The intracellular myoplasmic calcium concentration 
is modulated by three calcium pump sites to either sequester 
calcium intracellularly or to regulate calcium efflux from 
the cell. The sarcoplasmic reticulum and the mitochondria 
are capable of utilizing ATP to sequester calcium, while 
the calcium pump located in the surface membrane appears to 
be able to use the sodium gradient that exists across the 
membrane to transport calcium from the cell.
ii) Effect of caffeine, halothane and local anaesthetics
Although it has long been known that caffeine is
able to produce a contracture of skeletal muscle (Ransom,
1911; Hartree and Hill, 1924) the first direct evidence to
link the effect of caffeine with calcium movements within
the muscle was published by Bianchi in 1961. He showed that
45caffeine increased both the influx and efflux of Ca from 
frog skeletal muscle. This effect was present even if the 
fibres were depolarised with high external potassium 
concentrations.
Evidence accumulated over the 1960's and early 
1970's on the site of action of caffeine in skeletal muscle. 
Caffeine appears to have three distinct actions on frog 
sartorius muscle in relation to contracture. At low
11
concentrations (less than 1 mM) caffeine acts primarily on 
sites related to the coupling of the action potential to 
muscle contracture (Sandow and Preiser, 1964; Sandow, Taylor 
and Preiser, 1965; Brust, 1965; Sandow and Brust, 1966; 
Bianchi et al., 1967). Intermediate concentrations of 
caffeine (1-5 mM) cause a contracture which does not require 
membrane depolarisation and is reversible upon removal of 
caffeine (Axelsson and Thesleff, 1958; Matsushima, Fujino 
and Nagai, 1962). Concentrations of caffeine higher than 
5 mM cause rigor or irreversible contracture. The site of 
action of caffeine is believed to be the sarcoplasmic 
reticulum where it can cause a release of calcium and also 
block the uptake of calcium thus maintaining a high calcium 
level in the myoplasm (Herz and Weber, 1965; Weber and Herz, 
1968) .
Strobel and Bianchi (1971) demonstrated that 
halothane potentiated the caffeine contracture and this 
potentiation was prevented by procainamide. Feinstein (1963) 
had previously shown that procaine inhibited caffeine 
contractures and caffeine induce rigor.
An important finding was the first documentation 
by Kalow et al. (1970) that halothane potentiated the 
contracture produced by caffeine in human skeletal muscle. 
This was confirmed by Moulds and Denborough in 1972, who 
also demonstrated that the potentiation was inhibited by 
procaine. A comprehensive study on the effects of caffeine, 
halothane and procaine on normal human muscle was published 
in 1974 by Moulds and Denborough (1974a). Normal human
FIGURE 2
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skeletal muscle is more sensitive to caffeine and halothane 
than frog sartorius muscle, with 4 mM caffeine producing a 
slow small contracture in human muscle but producing rigor 
in frog muscle. Halothane does not usually induce a 
contracture in normal human muscle in vitro but small 
contractures may occur (Moulds and Denborough, 1974a;
Nelson, Austin and Denborough, paper in preparation).
Although the detailed molecular actions of halothane 
and caffeine are not known, the evidence available suggests 
that the excitation-contraction coupling mechanism is 
involved and that halothane does not inhibit the uptake of 
calcium into the sarcoplasmic reticulum (Moulds et al.,1974b).
The local anaesthetics procaine and tetracaine 
(see figure 2) block caffeine and halothane potentiated 
caffeine contractures in human muscle as well as muscle from 
a variety of animals (Austin and Denborough, 1975; Bianchi 
and Bolton, 1967). Some local anaesthetics can actually 
augment caffeine contractures however, and a detailed 
mechanism involving the charge state of the anaesthetic is 
reviewed by Seeman (1972).
C: Malignant hyperpyrexia skeletal muscle
i) Role of calcium
The detailed molecular mechanism in malignant 
hyperpyrexia involving intra-cellular muscle membranes and 
calcium movements cannot be fully realized until excitation- 
contraction coupling in normal muscle is more clearly
13
understood.
With respect to treatment, however, a detailed 
molecular view may not need to be established. The exact 
site of the primary lesion in malignant hyperpyrexia, if 
only a single lesion exists, may not be critical to studies 
on drug treatment. As long as the drugs studied inhibit 
calcium release from the sarcoplasmic reticulum, control of 
abnormal muscle response may be possible. The membrane 
abnormality may be present in the sarcolemma, in the 
sarcoplasmic reticulum, in the association of these two 
membranes or in mitochondria. At present no distinction 
between any of these possibilities can be made.
The general control mechanism of calcium movement 
in skeletal muscle from malignant hyperpyrexia patients 
appears to be normal and any abnormality only becomes 
evident upon exposure to halothane or succinylcholine.
Most of the in vitro work on whole muscle fibres and 
isolated membrane preparations has therefore been focussed 
on the effects of the clinical triggering agents.
ii) Effect of caffeine, halothane and local anaesthetics
Kalow et al. (1970) reported that muscle from 
patients susceptible to malignant hyperpyrexia gave an 
enhanced caffeine contracture and that halothane potentiated 
the caffeine response to a greater degree than that found in 
normal muscle. Although these workers stated that treatment 
with halothane alone did not cause a contracture, the 
temperature of the muscle buffer was 25°C. It has since
14
been shown that if the physiological temperature of 37°C is 
selected, a spontaneous contracture occurs upon exposure to 
halothane (Ellis et al., 1972; Moulds et al., 1972).
Recently, Moulds and Denborough (1974b) have shown that 
muscle from susceptible patients is supersensitive to 
potassium chloride, succinylcholine, caffeine, halothane and 
caffeine potentiated halothane treatments. They also 
reported that procaine partially reversed and inhibited 
halothane and succinylcholine contractures. This effect of 
procaine on halothane contractures in vitro has also been 
reported by Ellis, Keaney and Harriman (1973), Harriman,
Sumner and Ellis (1973) and Keaney and Ellis (1971).
Concentrations of caffeine too low to elicit a 
response in normal muscle (less than 4 mM) produce a large 
sharp response in malignant hyperpyrexia muscle (Moulds et 
al., 1974b). Since it is thought that low levels of caffeine 
affect the excitation-contraction coupling mechanism in 
skeletal muscle, sensitivity to low caffeine levels in 
effected muscle may reflect an excitation-contraction coupling 
abnormality. The speed of relaxation following such a 
contracture suggests that caffeine has no effect on the re­
uptake of calcium into the sarcoplasmic reticulum (Moulds 
et al., 1974b). Contractures of normal muscle induced by 
8 mM caffeine have a slow relaxation rate following peak 
tension, suggesting that this level of caffeine affects the 
calcium ATPase of the sarcoplasmic reticulum (Moulds and 
Denborough, 1974b).
15
D: Treatment of malignant hyperpyrexia
i) Suggested drug treatment regimes and their rationale
The use of procaine and procainamide (see figure 2) 
was based originally on the finding by Feinstein in 1963, 
that procaine blocked the rigor produced in frog muscle by 
caffeine.
Others later found that procaine would block or 
reverse contractures in malignant hyperpyrexia muscle induced 
by halothane in vitro (Moulds et al., 1972). For theoretical 
reasons procaine, which is known to accelerate calcium uptake 
into the sarcoplasmic reticulum and block its release, should 
be more effective in malignant hyperpyrexia than lignocaine 
which enhances the release of calcium from the same membrane.
In a preliminary report it was shown that procaine 
and procainamide inhibited and relaxed caffeine and caffeine 
+ halothane contractures in normal human muscle to differing 
degrees (Austin and Denborough, 1975). The treatment 
rationale may be summarised: malignant hyperpyrexia appears 
to result from an increased level of calcium in the myoplasm; 
the source of this calcium appears to be the sarcoplasmic 
reticulum; procaine and procainamide have both been shown to 
reduce the release of calcium from the sarcoplasmic reticulum 
and they should therefore be useful in controlling the syndrome 
in humans.
In contrast to the rationale for the use of procaine 
and procainamide, the use of dexamethasone and hydrocortisone
16
(see figure 2) appears to be empirical.
Dexamethasone and hydrocortisone effects on muscle 
metabolism have not been documented. The effects of these 
two drugs on normal muscle contractures in vitro induced by 
caffeine and caffeine + halothane are not known. A single 
report on the inhibitory effect of hydrocortisone on 
halothane induced contractures from a susceptible patient was 
made by Ellis et al. (1974). The in vitro test was supposed 
to support the apparently successful use of dexamethasone in 
treating a nitrous-oxide induced case of malignant 
hyperpyrexia. No reason was given as to why dexamethasone 
was chosen for the primary drug therapy. On the basis of 
this report treatment regimes including dexamethasone as the 
primary drug choice have already been tried (Raitt and 
Merrifield, 1974). An evaluation of the efficacy of these 
two steroids in antagonising in vitro muscle contracture was 
obviously required. Both dexamethasone and hydrocortisone 
were included in the present study.
Reports that dantrolene (see figure 2) could block 
excitation-contraction coupling without affecting caffeine 
contractures (Putney and Bianchi, 1974), neuromuscular 
transmission or electrical properties of muscle (Ellis and 
Carpenter, 1972; Ellis and Bryant, 1972; Ellis, Castellion, 
Honkomp, Wessels, Carpenter and Halliday, 1973) prompted 
Nelson and Denborough to use this drug to investigate its 
efficacy in antagonising contractures in normal human muscle 
(Nelson and Denborough, 1976, paper in preparation). The 
potency of its muscle relaxation properties is well documented
17
(Ellis et al., 1973), and prompted Harrison into using the 
drug to control malignant hyperpyrexia in sv/ine. Harrison 
(1975) demonstrated that dantrolene could be used to block 
initiation of malignant hyperpyrexia by halothane and also 
to terminate the established syndrome in swine. He reported 
a 100% survival rate when a high enough concentration of 
dantrolene was selected. Its apparent ability to interfere 
with the excitation-contraction coupling mechanism and 
caffeine-induced contractures in normal human muscle 
warranted further investigation.
ii) Selection of in vitro drug concentrations
Selection of appropriate in vitro drug concentrations 
is complex. Even when blood concentrations of a particular 
drug are well documented, the blood levels do not necessarily 
correlate with tissue levels. Doses recommended by a 
manufacturer and doses used by clinicians do not always agree 
and with some drugs there are wide discrepancies. Toxic 
levels of drugs may vary from one patient to another. Reports 
on successful treatment of malignant hyperpyrexia include a 
wide range of concentration units. Dosage levels reported 
in mg/Xg, total mg, mis of x%, mK final concentration, yg/ml 
as well as other units add a great deal of confusion. Drug 
levels tolerated by animals may produce toxic effects in 
humans.
As the main purpose of this study was the selection 
of the most appropriate drug for treatment of malignant 
hyperpyrexia, great care was required in the selection of 
in vitro concentrations. Indeed, inappropriate selection of
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in vitro drug concentrations by a number of workers, has led 
to recent criticism (Hall and Lister, 1974).
The use of procaine in the treatment of malignant 
hyperpyrexia has been suggested at levels many times the 
accepted toxic dose. The concentration of procaine used in 
model studies in vitro with caffeine-induced muscle 
contracture has varied from 2 mM to 10 mM (Beldavs, Small, 
Cooper and Britt, 1971; Relton, Steward, Creighton and Britt, 
1972; Hall et al., 1972; Kalow et al., 1970; Britt et al., 
1973; Feinstein, 1963; Bianchi and Bolton, 1967). Halothane- 
induced contracture in muscle from susceptible patients has 
been shown to be reduced by 1.8 mM to 5 mM procaine (Moulds 
and Denborough, 1972; Ellis, Keaney and Harriman, 1973; Hall 
and Lister, 1974).
These concentrations are higher than those 
recommended for clinical use. Not only would procaine 
concentrations of this magnitude induce hypotension but the 
rapid hydrolysis of procaine in the blood suggests the levels 
might be difficult to maintain (Wikinski et al., 1970; Hall 
and Lister, 1974).
Recommended clinical doses of dexamethasone to 
adults, range from 2 mg to 40 mg as a single intravenous 
injection. Further injections every 2 to 6 hours may be 
required for the treatment of severe shock (Oaks and Cohen, 
1967; Cavanagh and Singh, 1970). Rare dosages almost ten 
times those just mentioned have been reported making the 
selection of a clinical concentration difficult (Dietzman,
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Ersek, Bloch and Lillehei, 1969).
Two concentrations of each drug were selected to 
make allowances for such discrepancies, and to provide 
information about drug efficacy in relation to dosage. The 
lower concentration was selected to fall in the usual 
clinical range and the higher concentration of each drug 
studied, may be reached in emergencies. The difference, if 
any, between the two concentrations of a particular drug, 
would help to decide if the increased concentration, with 
the concomitant increased danger, was necessary or worthwhile.
Dantrolene Sodium
In contrast to the numerous reports on the 
effectiveness of dantrolene in controlling a variety of 
muscle complaints in humans, little is known about the blood 
concentrations that can be tolerated. Although dantrolene 
was first noted to have muscle relaxant properties in 1967, 
oral administration to humans has only been sanctioned in 
the United Kingdom since February, 1975. Parenteral use has 
yet to be approved in the United Kingdom or the United States 
of America (Snyder, Davis, Bickerton and Halliday, 1967; Ellis 
et al., 1975). Dantrolene is not yet available in Australia.
Clinical evaluation of the safety of dantrolene is 
therefore based on oral dosages. A typical treatment regime 
for disorders of the central nervous system would be 100 mg 
dantrolene by tablet four times a day. With this dose, blood 
levels of 2-3 yg/ml (6-9 yM) are attained with peak 
concentrations as high as 3.75 yg/ml (11 yM) (Chyatte and
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Birdsong, 1971; Chyatte, Birdsong and Bergman, 1971; Herman, 
Mayer and Hewcombe, 1972). A single dose of 150 mg orally 
results in a blood level in a normal adult of about 1.3 yg/ml 
(4 yM) four hours after ingestion (Herman et al., 1972). 
Assuming a blood volume of 5 litres and 100% absorption of 
the drug into the blood, an initial 150 mg dose would lead 
to a concentration of 30 yg/ml (89 yM). However, only about 
4% of this theoretical concentration is achieved. Failure 
of absorption from the intestine, hydrolysis or chemical 
degradation in the blood, deposition into tissues and 
excretion all play important roles in controlling steady- 
state blood levels of any drug. Because little is known 
about the concentration of drugs in tissues, blood levels 
are generallly used in in vitro experiments.
Harrison (1975) has suggested that dantrolene blood 
concentrations of about 80-100 yg/ml (237-297 yM) are 
necessary to prevent the onset of porcine malignant 
hyperpyrexia. Concentrations of dantrolene of this magnitude 
have not been achieved in humans, and a rising list of some 
minor side effects during clinical trials suggests that 
concentrations of dantrolene about 6-7 yg/ml (18-21 yM) should 
not be exceeded (Chyatte and Birdsong, 1971).
The two concentrations of dantrolene selected for 
use during this study were 6 yM and 30 yM; a level of 6 yM 
being easy to attain clinically and a level of 30 yM, which 
might be warranted in an emergency.
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Procaine Hydrochloride
Procaine is rapidly hydrolysed in human blood 
(Wikinski, Usubiaga, and Wikinski, 1970; Hall and Lister,
1974). Since the rate of hydrolysis probably varies and 
tissue levels are difficult to correlate with blood levels, 
the steady-state blood levels of procaine are practically 
unknown. Although toxic levels in blood are known for 
laboratory animals such as dogs, very little is known about 
toxic levels in humans (Wikinski et al., 1970). A dose of 
6.8 g is required, in theory, to produce a concentration of 
5 mM in the circulation of an adult (Moulds and Denborough, 
1972). However, the effect of procaine on caffeine-induced 
muscle contracture is dose dependent and so levels lower 
than 5 mM may still be useful (Moulds and Denborough, 1972).
Harrison (1971), on the basis of procaine treatment 
with malignant hyperpyrexia susceptible pigs suggested a 
loading dose of 30-40 mg/Kg (1.5-2.1 mM) in humans, but 
this concentration will almost certainly lead to convulsions 
and circulatory failure (Usubiaga et al., 1966; Wikinski et 
al., 1970; Hall and Lister, 1974). Hall and Lister (1974) 
suggest that 2 mM blood levels of procaine cannot be obtained 
safely while Usubiaga (1966) and his associates regard 
20-80 yg/ml (0.07-0.3 mM) as toxic in humans.
Attempts to achieve a dosage of 30 mg/Kg (~1.5 mM) 
appear to have contributed to the death of a patient in 1974 
(MacLachlan and Forrest, 1974). Severe hypotension was 
induced by procaine after only 600 mg of the suggested dose 
of 2,000 mg had been given over twenty minutes (Harrison, 1971)
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The hypotension was not reversed by isoprenaline. Rapid loss 
of active procaine levels in blood from 800 to 96 yg/ml 
occurs within five minutes of infusion (Wikinski et al., 1970). 
A loading dose of 600 mg over twenty minutes would probably 
result therefore in a relatively low blood level of procaine.
Although the patient described by Wikinski and his 
associates (1970) survived a procaine dosage of 4,000 mg, 
they ascribed the survival to youth, hyperventilation with 
100% oxygen, his otherwise good health and a lot of luck. 
Hyperventilation with 100% oxygen is known to inhibit and 
help reverse cardiac depression caused by overdoses of 
intravenous local anaesthetics (Doas, Lopez and Virtue, 1963). 
Wikinski's patient was being hyperventilated with 100% 
oxygen as the accidental overdose occurred.
In summary reasonably safe intravenous procaine 
administration probably ranges from 200-700 mg (0.1 -0.5 mM). 
The levels of procaine selected for this study were 0.5 mM 
as a concentration which was relatively safe and 5 mM.
Procainamide Hydrochloride (Pronestyl)
The clinical use of procainamide is similar to that 
for procaine. They are often used intravenously as anti- 
arrhythmic agents. Safe blood levels seem to correlate 
with levels possible with procaine. Dosages as high as 
700-900 mg (o.5 mM - 0.7 mM) and as low as 200 mg (0.1 mM) 
have been used in the successful treatment of malignant 
hyperpyrexia (Hall and Lister, 1974; Noble, McKee and Gates, 
1973; Brebner and Jozefowicz, 1974).
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The low concentration of procainamide used in this 
study (0.5 mM, 679 mg) was selected to fall in the middle of 
the range mentioned above and the high concentration was 
5 mM.
Dexamethasone and hydrocortisone
The use of dexamethasone or hydrocortisone in 
treatment regimes is relatively recent (Ellis et al., 1974; 
Raitt and Merrifield, 1974; Clarke and Ellis, 1974). Apart 
from the three references just cited no other serious attempt 
to control malignant hyperpyrexia by dexamethasone or 
hydrocortisone has occurred, to the knowledge of this author. 
Inadvertant use of steroids has occurred during treatments, 
but in these instances, relatively low levels have been used 
(Noble et al., 1973).
Two successful treatment courses have been reported 
with dexamethasone (Ellis et al., 1974; Raitt and Merrifield, 
1974). An 11 year old girl received 45 mg and the treatment 
initiated by Raitt was 4 mg (0.2 mg/Kg) to a 6 year old boy. 
Ellis et al. (1974) suggests dexamethasone doses of 1-2 mg/Kg 
(27-54 yM) . Clarke and Ellis (1974) feel that 100 mg (39 yM) 
dexamethasone as well as procaine should be given to an 
adult who develops malignant hyperpyrexia. Interestingly, the 
use of dexamethasone was suggested because of the peripheral 
vasodilation and positive inotropic effects on the myocardium, 
not because of any direct effect on skeletal muscle
metabolism.
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In the same publication that Ellis and his 
colleagues reported the successful treatment of malignant 
hyperpyrexia with dexamethasone, they presented in vitro 
evidence for an effect by hydrocortisone.
Although these results v/ere reported as preliminary, 
no conclusion can be drawn on the efficacy of hydrocortisone 
at clinical concentrations in inhibiting halothane-induced 
contractures. Results from the same study, do provide 
evidence however, that clinical levels of hydrocortisone 
(29 yM) can promote relaxation of a halothane-induced 
contracture. The successful use of steroids in the treatment 
of malignant hyperpyrexia reported by a number of workers 
and its inadvertant use by a few others during successful 
treatments, warrants a more detailed investigation.
A normal clinical dose of dexamethasone in the 
treatment of a large variety of disorders ranges from 2 mg 
to 20 mg (0.8 - 8 yM). Doses as high as 40 mg (16 yM) are 
used occasionally. However, a few instances of dexamethasone 
therapy about ten times this figure (~400 mg, 160 yM) have 
been reported (Dietzman et al., 1969). Similar variations 
in hydrocortisone administration are also seen with clinical 
doses via intravenous injections ranging from 100 mg to 
1000 mg (55 - 552 yM).
The low concentrations of dexamethasone and 
hydrocortisone used during this study were equivalent to 
dosages of 20 mg (7.8 yM) and 100 mg (55 yM) respectively. 
These levels are easily obtained clinically with very few
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side effects. The higher concentration of dexamethasone 
was 200 mg (77.5 yM) and 1000 mg (552 pM) for hydrocortisone.
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SECTION II - SELECTION OF THE MOST EFFECTIVE DRUG IN
THE TREATMENT OF MALIGNANT HYPERPYREXIA
A: Introduction
Anaesthetic-induced malignant hyperpyrexia appears 
to result from increased free calcium levels in the myoplasm 
of skeletal muscle cells (Kalow et al., 1970; Moulds and 
Denborough, 1972). Raised myoplasmic levels of calcium can 
be induced in susceptible muscle in vitro by a variety of 
drugs and physical stimuli (Moulds and Denborough, 1974b). 
Malignant hyperpyrexia muscle is more sensitive than normal 
muscle to these same drugs and physical stimuli. The exact 
site of the lesion in malignant hyperpyrexia is unknown, but 
the sarcolemma, sarcoplasmic reticulum and mitochondria have 
received most of the attention in recent years.
The lack of advancement in the treatment of 
malignant hyperpyrexia can be attributed primarily to the 
shortage of material. Malignant hyperpyrexia is a rare 
syndrome and muscle becomes available for testing only 
occasionally. Various models for malignant hyperpyrexia have 
therefore been proposed in an attempt to overcome this 
problem. The in vitro models include the use of normal human, 
frog and rat muscle, as well as pig muscle from susceptible 
swine.
B: Selection of an appropriate in vitro model for
malignant hyperpyrexia
Models of human malignant hyperpyrexia based on 
normal muscle from pigs, rabbits, rats or frogs may not be
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relevant, because of inter-species differences in muscle 
sensitivity to caffeine and halothane in vitro (Nelson,
Bedell and Jones, 1975; Clarke and Ellis, 1975; Feinstein,
1963; Austin, Nelson and Denborough, unpublished observations). 
Although porcine malignant hyperpyrexia has been suggested 
as a suitable model of the human syndrome, workers have 
recently thrown doubt on its suitability (Britt, Endrenyi 
and Cadman, 1975) . Even though basic differences between the 
two syndromes have been documented (Britt et al., 1975) many 
similarities warrant its further use as a model for 
malignant hyperpyrexia.
Drug treatment, however, implies human drug response. 
A particular drug effect in pig, rabbit or rat muscle does 
not necessarily guarantee the same effect in human muscle.
The selection of a single model for a comparative study of 
the many drugs now suggested as suitable treatments for 
malignant hyperpyrexia was required.
Recent studies on the action of various pharmacologic 
agents on human muscle by Moulds and Denborough (1974a) have 
enabled a suitable human model to be proposed. Muscle from 
susceptible patients develops a greater than normal in vitro 
contracture in the presence of caffeine (Kalow et al., 1970), 
halothane, potassium chloride and succinylcholine (Moulds 
and Denborough, 1974b). Caffeine contractures are potentiated 
to a greater than normal extent by the addition of halothane 
(Britt et al., 1973; Ellis and Harriman, 1973).
Treatment of normal muscle with low concentrations
of caffeine (2 mM) does not result in contracture. However, 
pretreatment of normal muscle with low concentration of 
caffeine (2 mM) potentiates a response to halothane (Moulds 
and Denborough, 1974a). Caffeine at levels of 8 mM induces 
contracture of normal human muscle in vitro (Moulds et al., 
1974a; Nelson, Austin and Denborough, unpublished observations). 
Caffeine-induced contractures and caffeine potentiated 
halothane-induced contractures in normal human muscle have 
both been suggested as suitable models for the in vitro study 
of malignant hyperpyrexia (Moulds et al., 1972; Kalow et al., 
1970; Britt et al., 1973).
The description of a study based on these two models 
for malignant hyperpyrexia follows. Two basic types of 
experiment were performed. A drug added before the 
contracture-inducing agents was an in vitro model to test 
drug prevention of malignant hyperpyrexia, while a drug added 
during a contracture was intended as a model to test drug 
reversal of the established syndrome.
The following experiments were designed to measure 
and compare the efficacy of six drugs in inhibiting and 
relaxing caffeine and caffeine potentiated halothane muscle 
contractures in vitro.
C: Materials and methods
i) Preparation of solutions
The buffer used to incubate the human muscle during 
this study was basically as described by Elford in 1970.
29
Muscle buffer which was continuously bubbled with carbogen 
(95% oxygen/5% carbondioxide) contained the following as 
final concentrations at pH 7.3: NaCl 121.2 mM, KC1 5.4 mM, 
CaCl2 2.5 mM, MgS04 1.2 mM, NaH2P04 1.2 mM, NaHCO3 15.0 mM
and glucose 11.5 mM. The muscle buffer was prepared daily 
from concentrated stocks by appropriate dilution to prevent 
contamination by fungal growth which occurred if the buffer 
was kept more than 72 hours.
Caffeine was freshly prepared before each experiment 
at a stock concentration of 100 mM in the standard muscle 
buffer.
It was technically difficult to administer both 
sudden and yet constant levels of halothane to the muscle 
buffer because of the volatility of this agent at 37°C.
A halothane vaporiser (DRÄGER VAPOR) was therefore selected 
which delivered a constant level of halothane to a stream 
of carbogen, which was then directed to the muscle bathing 
chamber. The VAPOR was calibrated and capable of delivering 
any level of halothane between 0.05% and 3.5%. Variations 
in the concentration of halothane with changes in room 
temperature were automatically compensated for by changing 
the instrument setting. The working range of the VAPOR was 
between room temperatures of 16°C and 30°C. Neither gas 
pressure nor gas flow affected the accuracy of the VAPOR.
Dantrolene sodium was prepared daily, as a stock 
solution of 148.7 \iM in 10 mM NaOH. Initial attempts to 
prepare solutions of dantrolene in the standard muscle buffer
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resulted in a milky-white suspension. An equal volume of 
buffer was removed if the volume of any drug to be added 
exceeded 1 ml. The resultant 20% change in the ionic 
composition when 5 mis of dantrolene was added did not appear 
to affect muscle response. Control experiments were performed 
to confirm that 2 mM NaOH (final concentration) did not affect 
muscle response.
Dexamethasone was supplied by the hospital pharmacy 
as dexamethasone sodium phosphate dissolved in water (8.5 mM). 
Dexamethasone sodium phosphate is a water soluble inorganic 
ester of Decasone and is about 25 to 30 times more potent than 
hydrocortisone. Sodium bisulfite (o.l%), methylparaben 
(0.15%) and propylparaben (0.02%) were added to the Decasone 
as preservatives by the manufacturer.
Hydrocortisone was supplied as Efcortelan Soluble. 
Efcortelan is a soluble ester of hydrocortisone and was 
supplied as a freeze-dried powder which was dissolved in 
water immediately before addition to the muscle bathing 
chamber. The standard vial contained 100 mg of hydrocortisone 
as hydrocortisone sodium succinate in 2 mis of water 
(137.9 mM) , buffered with Na2HP04 and NaH2P0i*.
Pronestyl was supplied as a 10% sterile aqueous 
solution (367.6 mM). Pronestyl for intravenous use contains 
benzyl alcohol (0.9%) and sodium bisulfite (0.09%) as 
preservatives. It is the amide analogue of procaine 
hydrochloride and is synonomous with procainamide. The pH 
had been adjusted to between four and six with HC1 or NaOH by
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the manufacturer. Such small volumes of pronestyl were 
being added to the muscle bath that no change in the pH of 
the buffer occurred.
Procaine and procainamide were both prepared as 
stock solutions of 250 mM in the standard muscle buffer at 
pH 7.3.
Dantrolene was a gift from the Norwich Pharmacal 
Company, U.S.A., and halothane was purchased from I.C.I. 
Australia. Procaine and procainamide were supplied by the 
Sigma Chemical Company and K & K Laboratories of the U.S.A. 
respectively. Pronestyl was manufactured by E. R. Squibb 
and Sons Pty. Ltd., Vic.; Efcortelan Injection by Glaxo 
Australia Pty. Ltd., Vic.; Decasone by Charles E. Frosst 
Australia Pty. Ltd., and caffeine by the Sigma Chemical 
Company, U.S.A.
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ii) The biopsy technique
The biopsy technique was based on the method 
developed by Moulds and Denborough (1974a). Strips of rectus 
abdominis muscle were obtained from patients undergoing 
elective abdominal surgery.
It was found necessary to attend each operation 
so that quick incubation of the muscle specimen was assured. 
Immediate immersion in buffer and aging of the muscle after 
biopsy were stressed by Moulds (1974) and were confirmed in 
this study to be of paramount importance. The biopsy was 
invariably performed at the start of each operation, before 
halothane was administered to the patient. Premedication 
agents and drugs used to intubate patients were found to 
have no effect on muscle response, confirming the finding 
by Moulds (1974) .
Human muscle shortened upon removal from a patient. 
A 3 cm length of muscle would shorten considerably in vitro 
sometimes as much as 50% of the length in vivo. There was 
some evidence to suggest that if shortening occurred with 
pig muscle, then the tension developed by a fibre would be 
drastically lowered (Nelson, 1974, personal communication). 
An attempt to control shortening included the development 
and routine use of a simple muscle biopsy clamp (figure 3). 
The clamp also ensured a fixed length and depth of muscle 
would be routinely obtained.
The muscle clamp shown in figure 3 was sterilized 
and presented to the surgeon immediately before each
FIGURE 3
FIGURE 4
DISSECTION OF MUSCLE INTO FIBRE BUNDLES
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operation. As soon as the surgeon made an incision through 
the rectus abdominis sheath, the clamp was placed over a 
section of the sheath at the site of incision. The clamp, 
with muscle attached between the two clips, was then removed 
from the patient and placed in standard muscle buffer at 
3 70 C .
The muscle specimen was then transported to the 
laboratory and placed in a large petri dish containing more 
buffer. The first incision was through the thinnest face 
of the muscle. A pair of forceps was inserted into the 
incision (figure 4) in order to separate the two distinct 
'planes' of muscle.
Bundles of fibres from the sample were isolated 
(2 cm x 2 mm x 2 mm) and small stainless metal rings tied 
on each end (figure 6). They were then placed in buffer at 
37°C with carbogen bubbling through the buffer continuously. 
Care was taken to ensure that the rings were not tied on too 
tightly. If this occurred, the thread would usually cut the 
muscle and muscle specimens would frequently break when 
contracture was induced. The finer the thread used the 
more samples would break due simply to cut muscle. A 
thicker thread, Ethicon size '00', was therefore selected 
and routinely used.
During 1975 it was noted that inter-fibre variation 
and fibre breakages were reduced in experiments with pig 
muscle, by tying applicator sticks to muscle fibres before 
sectioning them from the pig (Nelson, Austin and Denborough,
FIGURE 5
A MUSCLE FIBRE BUNDLE TIED TO A STICK
1"
FIGURE 6
A MUSCLE FIBRE BUNDLE TIED TO TWO RINGS
l
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unpublished observations). The technique ensured that muscle 
fibres did not shorten and that no stretching took place.
The rings were tied on to the muscle just before the fibres 
were cut off the sticks, ready for testing. On closer 
examination of the human technique it was found that some 
fibres were breaking during contracture even though extreme 
care had been taken not to cut the muscle with the thread.
It was also noted that more fibres broke towards the end of 
the day, perhaps up to 6 hours after removal from the patient 
Fatigue and deterioration around the site of ring attachment 
was clearly evident when fibres were examined closely. The 
area affected was restricted to about 1 mm on either side of 
the thread. Deterioration also took place with pig muscle 
where it was tied onto the stick, but when rings were tied 
on just before use they were placed a short distance away 
from the site of attachment, thereby avoiding the weakened 
area.
The human technique during this study was therefore 
extended to avoid muscle breakages by using applicator sticks 
Moulds (1974) had demonstrated that the muscle had to be tied 
very shortly after removal from a patient, and so sticks were 
used to facilitate this pre-requisite as well. Individual 
bundles of fibres were dissected carefully but not removed 
from the clamp. As each bundle was ready, an applicator 
stick was laid next to it, tied and then removed as shown in 
figure 5.
The fibres tied on to the sticks were then placed 
in buffer at 37°C and continuously bubbled with carbogen.
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When a fibre bundle was required, the rings would be tied 
onto the fibre, the fibre cut from the stick and placed into 
the muscle bathing chamber. The improvements in contracture 
were threefold; increased absolute contracture tension; 
decreased fibre-fibre variation between fibres from the 
same patient and greatly decreased incidence of muscle 
breakages during contracture.
Improvements in absolute tension during this study 
account for the apparent wide range of control tensions in 
some cases but were continuously monitored by appropriate 
controls. During the final stages of this study all fibres 
were routinely tied to sticks.
iii) Measurement of muscle response
For the test, a fibre bundle was either removed from 
the incubation vessel with the small metal rings attached, 
or removed from a stick with rings which had just been tied 
to it. The preparation was then added to a vertical 25 ml 
glass muscle bathing chamber which was maintained at 37°C, 
via a surrounding water jacket which was supplied by an 
accurately controlled water circulator.
The muscle chamber had two gas inlets to the 
interior of the vessel. Either carbogen or halothane + 
carbogen would be supplied to the chamber through these 
inlets. A tap at the bottom of the chamber was used to 
facilitate quick and easy removal of used buffer (figure 7). 
The rate of gas delivery was about 100 ccs/minute of carbogen 
or halothane + carbogen both of which were controlled with
FIGURE 7
THE EQUIPMENT FOR TESTING IN VITRO MUSCLE RESPONSE 
BEFORE THE ADDITION OF A MUSCLE FIBRE BUNDLE
1. VAPORISER
2. TRANSDUCER
3. MUSCLE CHAMBER
4. AMPLIFIER
5. RECORDER
6. WATER CIRCULATOR 
HAL. = HALOTHANE INLET 
CARB. = CARBOGEN INLET
AN ENLARGEMENT OF
THE MUSCLE CHAMBER
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accurate flow meters.
The supply of carbogen was split into two streams.
One stream went directly to the muscle bathing chamber, 
while the other was connected to a Dräger 'Vapor' halothane 
vaporiser, which was connected to the other gas inlet on the 
muscle chamber. A two-way gas valve was used to direct the 
main stream of carbogen either directly to the muscle 
chamber or to the halothane vaporiser. Two different circuits 
were used to eliminate the possibility of halothane 
contamination from gas tubing after a previous run with 
halothane (figure 7). The 'Vapor' actually delivered a very 
low concentration of halothane (0.1%) even when set on 0%, 
hence the need for an independent by-pass.
One of the rings from the fibre bundle was placed 
over a metal hook which was attached to a Watson-Victor 
force transducer. The transducer was fixed to a sliding 
block which could be gently raised or lowered. The other 
ring was fixed to a glass rod and the piece of muscle gently 
tensioned initially to less than one gram. The signal from 
the transducer was amplified by a Sanei strain gauge 
amplifier and monitored by a Perkin-Elmer continuous chart 
recorder. The system was calibrated by hanging appropriate 
weights on the transducer, and adjusting the pen travel on 
the recorder.
The muscle bathing chamber with 25 mis of standard 
buffer was raised to cover the muscle sample, recorder 
switched on and tension adjusted to one gram.
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A steady baseline was obtained, and drugs were added 
to the buffer surrounding the muscle via disposable syringes 
or micro syringes depending on the volume to be added. If 
volumes greater than 1 ml were to be added to the bath, an 
equal volume of buffer was removed before the addition.
The system just described was duplicated and set up 
in a fume hood in order to eliminate halothane contamination 
of the laboratory atmosphere.
The duplication of the system served three main 
purposes. Firstly, the muscle bundles could be tested twice 
as quickly as a single system, hence reducing muscle aging 
to a minimum. Secondly, as a consequence of the decreased 
experimental time, two experiments were often performed 
during the day, thereby generating twice as much information. 
This was impossible when only a single system was used 
because it took up to 11-12 hours before all the fibre 
bundles had been tested. Thirdly, duplicate systems enabled 
better experimental quality control.
iv) Experimental variation and numerical analysis
The methods just described include two basic sources 
of variation. Fibre-fibre variation with fibres from the 
same patient was moderate but considered quite tolerable.
This variation was thought initially to be due mainly to 
muscle deterioration over the six hours of a typical 
experiment. General muscle response fell progressively from 
the time of removal from the patient.
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FIGURE 8
MUSCLE RELAXATION INDUCED BY DRUGS AT
CLINICAL CONCENTRATIONS IN VITRO
CONTROL
PROCAINE
CONTROL
3%
HALOTHANE
[ DANTROLENE
PROCAINE
2mM
CAFFEINE
8mM CAFFEINE
DANTROLENE
Procaine (0.5 mM) and dantrolene (6 yM) were added to 
the muscle bath when the contractures had reached steady- 
state levels. The arrows indicate the points at which 
drugs were added to the normal human muscle preparations.
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Patient-patient variation was a little more 
difficult to quantitate. The source of the variation 
appeared to be a real difference in sensitivity to caffeine 
or caffeine + halothane between patients.
The total amount of information generated during 
this study amounted to over thirty-five thousand (35,000) 
variables. Manipulation of the data by hand became a time 
consuming exercise, even after the completion of very few 
experiments. A comprehensive, versatile computer system 
was therefore developed to assist in the analysis of the 
data (see Appendix).
D: Results
i) Drug effects at clinical concentrations on normal human 
muscle
a) Drug induced relaxation
Examples of drug induced relaxation of 
caffeine contractures are shown in figure 8. After obtaining 
a baseline at a resting tension of about 1 gram, contracture 
was induced by the addition of 8 mM caffeine. Within one to 
two minutes a peak tension was reached which was followed by 
a short relaxation phase. Relaxation approached a steady- 
state level of tension after about four minutes, following the 
addition of the caffeine. If dantrolene or procaine were 
added at this point, immediate and sustained relaxation 
occurred. Relaxation induced by procaine was obviously not 
as great as that induced by dantrolene. Both drugs were at 
clinical concentration levels. None of the other drugs
studied had a significant effect on relaxation.
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Examples of typical contractures induced by caffeine 
potentiated halothane are also shown in figure 8. It can 
be seen that no contracture occurred upon addition of 2 mM 
caffeine. With normal muscle, contractures were not usually 
induced by halothane, but if caffeine (2 mM) was present 
in the muscle buffer, the addition of halothane (3%) resulted 
in a contracture of about 9 g.
Appropriate drugs were added to the muscle bath 
during the relaxation steady-state level as before. The 
effect of dantrolene at a clinical concentration was dramatic. 
Almost complete relaxation was immediately induced and 
maintained. Procaine induced a small degree of relaxation.
No other drug tested appeared to induce relaxation.
Each experiment was repeated with a minimum of five 
fibres and usually on more than three patients. A summary 
of the results obtained on all drugs tested is presented in 
table 1.
Relaxation is presented as the percentage drop in 
tension following the addition of a drug. Procainamide, 
hydrocortisone and dexamethasone failed to induce relaxation 
following either type of contracture. The P value was 
obtained by a t-test between the data from dantrolene and 
each of the other drugs. It can be seen from table 1 that the 
degree of relaxation induced by dantrolene is significantly 
greater than all the other drugs including procaine. The 
difference between the effect of dantrolene on caffeine 
contractures and caffeine + halothane contractures was not
3Va
FI GUMS 9
INHIBITION OF AN 8mM CAFFEINE CONTRACTURE BY DANTROLENE 
AT A CLINICAL CONCENTRATION IN VITRO
2 MIN
8mM CAFFEINE
DANTROLENE
Dantrolene (6 yM) was added to the normal human 
muscle about 6 minutes before the caffeine.
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FIGURE 10
INHIBITION OF A 2mM CAFFEINE + 3% HALOTHANE CONTRACTURE 
BY DANTROLENE AT A CLINICAL CONCENTRATION IN VITRO
2 MIN
2mM
CAFFEINE
3%
HALOTHANE
t
DANTROLENE
Dantrolene (6 pM) was added to the normal human 
muscle about 6 minutes before the caffeine.
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statistically significant. Procaine, on the other hand, did 
have a greater effect on caffeine compared to caffeine + 
halothane contractures and this was significant at the 2% 
level.
b) Drug inhibition of 8 mM caffeine contractures
The inhibitory effect of a drug was 
measured by recording the tension developed by 8 mM caffeine 
in the presence and absence of the drug.
An example of the inhibitory effect of dantrolene 
on an 8 mM caffeine contracture is shown in figure 9. 
Dantrolene not only inhibited the peak tension produced but 
also prolonged the time to peak contracture.
The results for all drugs tested at clinical 
concentrations are presented in table 2. Dantrolene inhibited 
8 mM caffeine contracture by about 75%. No other drug tested 
in this series significantly inhibited caffeine contractures.
c) Drug inhibition of 2 mM caffeine + halothane 
contractures
The inhibiting effect of dantrolene on a 
2 mM caffeine potentiated halothane contracture is shown in 
figure 10. Pre-treatment of a fibre with dantrolene inhibits 
the caffeine + halothane contracture in normal human muscle 
by about 60%. No other drug suggested for the treatment of 
malignant hyperpyrexia at a clinical concentration had a 
significant effect on caffeine + halothane contractures 
(table 3). There was a strong suggestion that procaine
41
inhibited the contracture slightly (-20%) but this was not 
statistically significant (P>0.06).
The apparent discrepancies between controls can be 
explained by the differences in caffeine and halothane 
sensitivity in different patients. Occasionally the two or 
three patients selected were more sensitive than usual to 
a particular drug combination, thus giving a high control 
mean.
ii) Drug effects at high concentrations on normal human 
muscle
Drug concentrations used in this study were above 
the usual levels recommended clinically. The levels of 
hydrocortisone, dexamethasone and dantrolene may be achieved 
clinically but the concentrations of procaine, procainamide 
and pronestyl would be dangerous to attempt in vivo.
Pronestyl is a trade name for a clinical sample of 
procainamide. There are however, other additives present 
as discussed in the Materials and Methods section. The 
effect of the benzyl alcohol in the pronestyl mixture was 
investigated following reports that lower alcohols can 
potentiate the effects of local anaesthetics on muscle 
calcium stores (Grist, Hall and Baum, 1973; Clarke and Ellis, 
1975; Ehrenpreis, 1965; Seeman, Chau, Goldberg, Sauks and 
Sax, 1971). Any difference between procainamide and pronestyl 
would be due to the preservatives added to the pronestyl.
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a) Drug induced relaxation
Typical results obtained with the six drugs 
studied on 8 mM caffeine induced contractures are presented 
in figure 11. Dantrolene immediately and completely reversed 
a caffeine contracture and the relaxation was sustained. 
Procaine also caused immediate relaxation, but the extent 
of reversal was less than for dantrolene. Although 
procainamide also caused relaxation its effect was not nearly 
as pronounced as procaine. Dexamethasone and hydrocortisone 
had no significant effect on caffeine contractures.
Pronestyl caused a secondary contracture to take place on 
top of the caffeine steady-state tension. A subsequent study 
revealed that benzyl alcohol at the same levels present in 
pronestyl would produce a similar contracture. Benzyl 
alcohol did not induce a contracture in muscle that had not 
been treated with caffeine.
Examples of normal muscle reaction to the various 
drugs during caffeine potentiated halothane contractures are 
shown in figure 12. Although the results for dantrolene, 
procaine and procainamide appear similar to those obtained 
with caffeine induced contractures, the responses to the 
other drugs are different. Dexamethasone had no effect on 
tension response, hydrocortisone caused substantial 
relaxation, and pronestyl promoted the same degree of 
relaxation as procainamide.
A summary of the experiments on the effects of these 
drugs on muscle tension during caffeine and caffeine 
potentiated halothane contractures is shown in table 4.
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Relaxation is presented as a percentage drop in muscle tension 
in relation to tension developed just before the addition of 
the drug. Dantrolene usually promoted relaxation to such 
an extent that the final tension was often below the initial 
resting tension.
The results for each drug have been compared with 
those obtained with dantrolene by the Student's t-test. 
Dantrolene was significantly more efficient in promoting 
muscle relaxation for both types of contracture when compared 
with all the other drugs (table 4).
Apart from the results obtained with dantrolene, two 
results require further emphasis. The augmenting effect of 
pronestyl on 8 mM caffeine contractures contrasts with a 
substantial relaxing effect of pronestyl when added to 
caffeine potentiated halothane contractures.
The addition of hydrocortisone to the muscle bath 
during a caffeine potentiated halothane contracture, resulted 
in the muscle tension being reduced by about 33%. In 
contrast, hydrocortisone appeared to have no relaxing effect 
on caffeine contractures (table 4).
b) Drug inhibition of 8 mM caffeine contractures 
The effect of procaine and dantrolene on 
the development of 8 mM caffeine contractures is shown in 
figure 13. None of the other four drugs tested had any 
effect on the tension developed by the fibres. Both dantrolene 
and procaine prolonged the onset of contracture and the size
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INHIBITION OF 2mM CAFFEINE + 3% HALOTHANE CONTRACTURES
BY DRUGS AT HIGH CONCENTRATIONS IN VITRO
2 MIN
CONTROL
HYDROCORTISONE
PROCAINE
DRUG
DANTROLENE
2mM CAFFEINE 3% HALOTHANE
Hydrocortisone (552 yM), procaine (5 mM) and 
dantrolene (30 pM) were added to the normal human 
muscle about 6 minutes before the caffeine.
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of the peak tension. The inhibitory effect on absolute peak 
tension produced was similar for the two drugs. A summary 
of the results of peak tensions produced by 8 mM caffeine 
following pre-treatment of the muscle with each drug is 
presented in table 5.
The inhibitory effects of dantrolene and procaine 
are similar, both reducing caffeine contractures to between 
15 to 20% of the tension developed in the absence of the 
drug. Although tension figures presented in table 5 would 
appear to suggest a potentiation of 8 mM caffeine 
contractures by pronestyl, the difference between the means 
was not statistically significant. Neither hydrocortisone, 
procainamide, pronestyl, nor dexamethasone treatments were 
statistically different from the appropriate controls 
(table 5).
c) Drug inhibition of 2 mM caffeine + 3% halothane 
contractures
Some of the inhibitory effects at the 
higher drug concentrations studied are shown in figure 14. 
The caffeine potentiated halothane contracture is a 
particularly severe test for the efficiency of any drug to 
inhibit. Dantrolene was the most efficient drug in 
inhibiting such contractures.
Hydrocortisone had a substantial inhibitory effect 
on caffeine potentiated halothane contractures, although to 
a lesser extent than dantrolene or procaine.
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The relative efficacy of all drugs tested can be 
seen in table 6. In contrast to the results presented for 
caffeine induced contractures in normal muscle, three results 
were significant.
Dantrolene inhibited the caffeine potentiated 
halothane contracture routinely by about 75%, procaine by 
about 65%, and hydrocortisone by approximately 40%. 
Procainamide and pronestyl did not appear to affect muscle 
contracture.
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E: Discussion
Results comparing the relative efficacy of five 
drugs in inhibiting and relaxing caffeine and caffeine + 
halothane contractures in vitro, in normal human muscle have 
been described. Each of the five drugs has been suggested 
as a suitable treatment for malignant hyperpyrexia. However 
most proposals have been empirical (see Section I, D;
British Medical Journal, 1968; Harrison, 1971; Ellis, Clarke, 
et. al., 1974). The efficacy of a particular drug in 
inhibiting or relaxing caffeine or halothane induced 
contractures in malignant hyperpyrexia muscle is the main 
basis used to justify a specific treatment (Ellis, Clarke, 
et. al., 1974; Moulds and Denborough, 1972; Ellis, Keany and 
Harriman, 1973).
The shortage of human malignant hyperpyrexia muscle 
for experimental studies necessitated the use of a normal 
muscle model. The justification of the model with normal 
muscle was as follows:
1. Drugs that have been shown to reverse halothane 
contractures in malignant hyperpyrexia muscle 
have similar effects on contractures induced
in the normal muscle model.
2. Malignant hyperpyrexia muscle is particularly 
sensitive to caffeine, halothane and caffeine 
potentiated halothane contractures. Similar 
types of contracture can be simulated in
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normal muscle, by either increasing the 
concentration of caffeine, or by pre-treating 
muscle with low levels of caffeine and then 
exposing the muscle to halothane.
3. The mechanism of the abnormal release of
calcium into the myoplasm which occurs using 
these agents, appears to be similar for both 
types of muscle.
The results presented in table 1, show that 
dantrolene and procaine were the only drugs tested at usual 
clinical levels, that caused significant relaxation of 8 mM 
caffeine contractures. Dantrolene was far more effective in 
promoting relaxation than procaine (-107% compared to only 
-20%, table 1). A similar result was obtained if relaxation 
of caffeine + halothane contractures was used as the model 
(-97% compared to only -ll%m table 1). Reports on the 
efficacy of procaine in antagonising muscle contracture in 
normal and malignant hyperpyrexia muscle have involved very 
high dosage levels (see Section I, D, Clarke and Ellis,
1975; Moulds and Denborough, 1972). Moulds and Denborough 
(1972), suggested that the procaine effect was dose dependent 
and that lower levels of procaine at clinical concentrations 
may be effective. The results presented in table 1 appear 
to be the first reported effects at therapeutic levels, of 
procaine on caffeine and caffeine + halothane contractures 
in normal human muscle (Clarke and Ellis, 1975; Hall and
Lister, 1974).
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Although procaine failed to inhibit the onset of 
either type of contracture (tables 2 and 3), its effect in 
promoting relaxation may still be relevant to the treatment 
of malignant hyperpyrexia once the syndrome has been 
triggered (table 1). However, any academic discussion 
involving the usefulness of procaine as a treatment for 
malignant hyperpyrexia is overshadowed by the dramatic 
effects of dantrolene (tables 1, 2 and 3). Dexamethasone, 
hydrocortisone and procainamide did not have any effect on 
inhibiting or relaxing either type of contracture (tables 1, 
2 and 3).
Similar experiments to those just discussed but 
with higher drug concentrations are summarised in tables 
4 to 6.
Dantrolene appeared to be no more effective at the 
higher concentration than at the lower level. This is not 
surprising as total relaxation of both types of contracture 
occurred at the lower drug level.
Procaine, on the other hand, showed a marked 
increase in its relaxation effect at the higher dose (compare 
table 1 with table 4). Dantrolene was equally effective in 
inducing relaxation with both types of contracture, but 
procaine was always more effective in reversing caffeine 
contractures than caffeine + halothane contractures (table 4).
Procainamide, in contrast was usually more 
effective in reversing a caffeine + halothane contracture
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than a caffeine contracture.
Even though procainamide had no effect in causing 
relaxation of either type of contracture at the clinical 
dose, an effect could be demonstrated at the higher dose 
(table 4). The degree of relaxation of caffeine contractures 
was appreciably less with procainamide than with procaine 
(-15% compared with -82%, table 4).
The only drug which was not effective in inhibiting 
caffeine contractures at the normal clinical concentration 
and which became effective at the higher level, was procaine 
(tables 2 and 5). Although the extent of suppression at 
5 mM would infer that lower quantities of procaine might 
restrain caffeine contractures, 0.5 mM procaine failed to 
impair contracture development (table 2). A blood level of 
0.5 mM is relatively high for clinical use and would be 
difficult to exceed. Hydrocortisone, dexamethasone and 
pronestyl failed to suppress or reverse caffeine contractures 
even at elevated concentrations (tables 4 and 5).
Dexamethasone also had no detectable effect on 
caffeine + halothane contractures (table 4). Although 
procaine appears superior to hydrocortisone in suppressing 
caffeine + halothane contractures, 5mM procaine is a toxic 
level, whereas 552 viM hydrocortisone may be possible to 
obtain in vivo (table 6).
The relevance of all drugs tested, except dantrolene, 
in the treatment of malignant hyperpyrexia is doubtful.
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Although procaine was a powerful inhibitor of caffeine and 
caffeine + halothane contractures at excessive therapeutic 
levels, clinical levels had very little effect.
Hydrocortisone did influence muscle tension at 
the higher level studied. At a concentration of 552 yM, 
which may be possible to obtain in vivo, it hampered the 
onset of caffeine + halothane contractures as well as 
inducing considerable relaxation. It failed to alter muscle 
tension with caffeine alone as the stimulant, so its use in 
the prevention or treatment of malignant hyperpyrexia 
therefore depends on which normal muscle model is the more 
relevant. Two points should be stressed, however; firstly, 
hydrocortisone is more effective in antagonising muscle 
contracture than dexamethasone, and secondly the potency 
of dantrolene overshadows any effect by hydrocortisone.
Procainamide failed to alter muscle response when 
administered at clinical concentrations in vitro. Even at 
levels far in excess of those possible to obtain clinically, 
only relatively small relaxation responses were detectable 
and no inhibitory activity could be demonstrated. The 
alcohol present in pronestyl actually augmented caffeine 
contractures. Preservatives added to commercial drug 
preparations that are presented in soluble form may cause 
an adverse response in vivo. The preservatives present in 
dexamethasone may account for the difference in muscle 
response in vitro between it and hydrocortisone. The 
relative efficacy of procaine and procainamide in interfering 
with muscle contracture in vitro, would support procaine
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as the more appropriate drug in any treatment regime. If, 
for example, procaine or procainamide were to be used to 
control cardiac arrythmia, procaine would be the better 
choice because of its added effect on skeletal muscle 
metabolism.
The observations just described imply that 
dantrolene would be the drug of choice in the treatment of 
malignant hyperpyrexia. At easily obtained blood levels, it 
completely reversed 8 mM caffeine as well as caffeine + 
halothane contractures; suppressed the induction of 8 mM 
caffeine by -75% and caffeine + halothane contractures by 
-60%; and was far more effective than any other drug 
suggested for the treatment of malignant hyperpyrexia at 
equivalent concentrations.
The most relevant model for malignant hyperpyrexia 
using normal muscle is difficult to ascertain. Both caffeine 
contractures as well as caffeine potentiated halothane 
contractures have been suggested. Evidence available at 
present suggests that caffeine and halothane may be acting 
at two distinct sites in human muscle (Nelson and Denborough, 
1976, paper in preparation). Since the location of the 
lesion in malignant hyperpyrexia muscle is unknown, the 
significance of any differences of one model over the other 
is unclear. Nevertheless, the potency of dantrolene is both 
highly impressive and unprecedented.
The capability of dantrolene to inhibit both types 
of contracture suggests it may be extremely effective in
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preventing the triggering of malignant hyperpyrexia in vivo. 
If this is the case, a great range of general anaesthetics 
become available for use in surgery on malignant hyperpyrexia 
patients. At present anaesthetists are limited in the choice 
of agents that can be used. Anaesthetic agents thought to 
have been safe in the past may induce a reaction in some 
patients as shown recently by Ellis et al. (1975). Pre­
treatment of the patient with dantrolene before anaesthesia 
may render such drugs safe. The finding that dantrolene 
completely reversed muscle tension and sustained the 
relaxation produced implies it may also be used in the 
treatment of malignant hyperpyrexia.
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SECTION III ~ DRUG EFFECTS ON HUMAN MALIGNANT
HYPERPYREXIA MUSCLE
A: Introduction
The opportunity to confirm the selection of the 
most effective drug in the treatment of malignant hyperpyrexia 
came at the conclusion of the experimental program just 
described. A serum creatine phosphokinase estimation was 
performed on a thirty-five year old male patient, whose 
brother had died from malignant hyperpyrexia, and found to 
be raised.
Raised serum creatine phosphokinase levels provide 
a relatively good indication of susceptibility to malignant 
hyperpyrexia, although occasional reports of normal levels 
in susceptible individuals have occurred (Ellis, Clarke, 
Modgill, Currie and Harriman, 1975). The raised creatine 
phosphokinase in this patient warranted further investigation, 
particularly when his family history was considered. The 
patient therefore returned to Canberra Hospital to have the 
definitive in vitro muscle test as described by Moulds and 
Denborough (1974c).
The first few muscle fibre bundles tested confirmed 
that the patient was susceptible to malignant hyperpyrexia. 
Some of the remaining fibres were than used to test the 
efficacy of some of the drugs tested earlier, in controlling 
the onset and relaxation of halothane and caffeine induced
contractures.
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B: Materials and methods
The materials and methods were basically the same 
as those described for normal muscle. The muscle clamp and 
stick technique was used as with normal muscle but the muscle 
biopsied was vastus lateralis (left leg). Two clamps were 
used.in order to obtain as many fibre bundles as possible.
The large muscle bulk of his thigh made this possible with 
little discomfort to the patient. The operation was 
performed under local anaesthesia (procaine) in case the 
patient was susceptible to malignant hyperpyrexia. Procaine 
was selected because of its demonstrated safety in malignant 
hyperpyrexia as opposed to lignocaine, which has been shown 
to enhance calcium release from the sarcoplasmic reticulum in 
vitro (Moulds et al., 1972). Care was taken by the surgeon 
not to inject procaine into the muscle sheath.
C: Pvesults
i) Confirmation of patient susceptibility to malignant 
hyperpyrexia
Succinylcholine, a muscle relaxant often used 
before general anaesthesia to facilitate intubation, is a 
potent precipitator of malignant hyperpyrexia in humans and 
swine (Hall, et al., 1966). Although this agent induces an 
in vitro muscle contracture in susceptible individuals, it has 
no effect on normal muscle (Moulds and Denborough, 1974a and b).
Depolarization of the sarcolemma membrane may be 
artificially induced by the rapid addition of potassium 
chloride to the muscle buffer. A concentration of 60 mM
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FIGURE 15
INHIBITION OF MALIGNANT HYPERPYREXIA MUSCLE CONTRACTURES
BY CLINICAL CONCENTRATIONS OF DANTROLENE IN VITRO
DANTROLENE t
Dantrolene (6 yM) was added to the human malignant 
hyperpyrexia muscle about 6 minutes before the drug 
being tested. The four treatments shown above do not 
induce a response in normal muscle.
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potassium chloride ensures complete depolarization in frog 
muscle (Luttgau and Oetliker, 1968). A level of 80 mM 
potassium chloride when added to normal human muscle however 
fails to cause a contraction (Moulds and Denborough, 1974b).
If human malignant hyperpyrexia muscle is treated with 80 mM 
potassium chloride an immediate contraction takes place.
The fact that low levels of caffeine (<2 mM) do 
not cause normal muscle to contract in vitro, has been 
discussed in previous sections. Occasionally small 
contractures could be induced by 3% halothane in normal 
muscle; however they were seldom over 0.2 g.
Confirmation of the susceptibility of the patient 
to malignant hyperpyrexia was obtained following tests on 
four fibres (figure 15). Large spontaneous contractures 
occurred when the fibres were exposed to halothane (3%), 
potassium chloride (80 mM) , succinylcholine (1 mil) and a low 
level of caffeine (2 mM) (figure 15). Treatment of normal 
muscle with the same agents causes no effect (Moulds and 
Denborough, 1974b).
Total inhibition of all four types of contracture 
by dantrolene at a clinical concentration is also shown in 
figure 15.
ii) Drug inhibition of malignant hyperpyrexia muscle 
contracture
The comparative effects of dantrolene at a clinical 
concentration and hydrocortisone and dexamethasone at high
FIGURE 16
5 5a
INHIBITION OF HALOTHANE CONTRACTURES 
IN MALIGNANT HYPERPYREXIA MUSCLE IN VITRO
DEXAMETHASONE
2 MIN.
CONTROLHALOTHANEDRUG
HYDROCORTISONE
DANTROLENE
Dexamethasone (7.75 MM), hydrocortisone (55.2 pM) 
and dantrolene (6 pM) were added to the human 
malignant hyperpyrexia muscle about 6 minutes before 
the halothane.
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FIGURE 17
RELAXATION OF HALOTHANE CONTRACTURES IN MALIGNANT 
HYPERPYREXIA MUSCLE BY CLINICAL CONCENTRATIONS OF DRUGS IN VITRO
2 MIN. 6yM DANTROLENE
3% HALOTHANE
DEXAMETHASONE
CONTROL
The drugs being tested were added to the human 
malignant hyperpyrexia muscle when the halothane 
contracture had reached a constant rate of relaxation.
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concentrations, in inhibiting halothane induced contractures 
can be seen in figure 16.
Dantrolene was the most efficient drug tested in 
inhibiting halothane induced contracture of malignant 
hyperpyrexia muscle (figure 16). Clinical (not shown) and 
high concentrations of hydrocortisone appeared to have 
similar inhibitory effects on halothane contractures. This 
lack of dose dependency by hydrocortisone requires further 
investigation as these treatments were not repeated. 
Dexamethasone, at relatively high levels, failed to inhibit 
a halothane induced contracture, in contrast to hydrocortisone 
The suppression of halothane contractures by dantrolene 
overshadows the moderate response induced with hydrocortisone.
iii) Drug induced relaxation of malignant hyperpyrexia muscle
Unfortunately, due to lack of fibres, the efficacy 
of only two drugs in relaxing halothane induced contractures 
in malignant hyperpyrexia muscle could be tested. Dantrolene 
at a clinical level caused total, immediate and sustained 
relaxation to halothane induced muscle contracture (figure 17) 
Dexamethasone, at clinical levels however failed to alter the 
rate of relaxation during a similar contracture (figure 17).
The concentration of dantrolene used on malignant 
hyperpyrexia muscle was at a clinical level, but the efficacy 
of the drug warranted investigation at even lower concentra­
tions. The reversal of a 3% halothane contracture and a 2 mM 
caffeine contracture by 3 yM dantrolene is shown in figure 18.
FIGURE lb
5 öu
DRUG INDUCED RELAXATION OF MALIGNANT HYPERPYREXIA 
MUSCLE CONTRACTURES BY LOW CONCENTRATIONS 
OF DANTROLENE IN VITRO
2 MIN.
3pM DANTROLENE
3% HALOTHANE
3pM DANTROLENE
t
2mM CAFFEINE
The dantrolene was added to the human malignant 
hyperpyrexia muscle when the contracture had reached 
a constant rate of relaxation.
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FIGURE 19
THE EFFECT OF HALOTHANE
ON NORMAL AND MALIGNANT HYPERPYREXIA MUSCLE IN VITRO
4 _
TENSION
MALIGNANT HYPERPYREXIA MUSCLE
NORMAL MUSCLE
HALOTHANE CONCENTRATION
A total of 132 muscle fibres (Rectus Abdominis) 
from 58 normal subjects and 6 fibres (Vastus Lateralis) 
from a patient susceptible to malignant hyperpyrexia 
were tested in vitro. The number of observations were 
as follows: normal muscle, 4% (11), 3% (60), 1% (7),
0.4% (54); malignant hyperpyrexia muscle, 3% (4), 1% (1) ,
0 .2% (1).
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iv) Halothane sensitivity of malignant hyperpyrexia muscle 
Muscle from patients susceptible to malignant 
hyperpyrexia is much more sensitive to halothane than normal 
muscle (figure 19). Perhaps a lower concentration of 
halothane could be used in future investigations. The results 
demonstrate the extreme sensitivity of malignant hyperpyrexia 
muscle to very low levels of halothane.
D: Discussion
Drug efficacy in suppressing and relaxing halothane 
and caffeine contractures in muscle from a patient 
susceptible to malignant hyperpyrexia has been measured. 
Contractures induced by halothane, succinylcholine, potassium 
chloride and caffeine were all abolished by low levels of 
dantrolene (6 yM). Evidence available for its action on 
human muscle suggests that dantrolene may act at two sites, 
depending on its concentration (Nelson and Denborough, 1976, 
paper in preparation). At low concentrations (<3 yM) it 
affects the excitation-contraction coupling apparatus, while 
at high levels (>6 yM) also acts on the sarcoplasmic 
reticulum. The obliteration of the large halothane and 
succinylcholine contractures by dantrolene is striking. This 
is the first reported effect of dantrolene at clinical levels 
on halothane or succinylcholine contractures induced in human 
malignant hyperpyrexia muscle in vitro. The overwhelming 
confinement of contractures induced by two of the most potent 
precipitators of malignant hyperpyrexia in vivo, by dantrolene 
is impressive. This drug was equally effective in preventing 
and reversing halothane contractures (figures 15 and 17).
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By contrast the results for dexamethasone and 
hydrocortisone were variable and unimpressive. Dexamethasone 
at normal clinical levels failed to alter the relaxation 
phase of a halothane contracture, and even at a high 
concentration had no inhibitory action. Hydrocortisone 
however did inhibit a halothane contracture by about 40%, 
but no dose dependent effect could be demonstrated.
Relaxation of halothane induced muscle contractures by 
hydrocortisone was not measured because of the lack of 
material. One fibre pre-treated with low concentrations of 
dexamethasone gave a relatively poor response, however, this 
was thought to be due to a poor fibre rather than a real 
effect. The treatment at the highest level of dexamethasone 
lends support to this conclusion, since no inhibitory action 
was detected.
Extensive studies on the site of action and 
therapeutic value of dantrolene have been reported in recent 
years (Gilly and Costantin, 1974; Putney and Bianchi, 1974). 
Studies with dantrolene on human muscle suggest that at low 
concentrations (<3 yM) its main site of action is the 
excitation-contracture coupling mechanism in the sarcolemma. 
At higher concentrations an effect on the sarcoplasmic 
reticulum can also be demonstrated (Nelson and Denborough, 
1976, paper in preparation).
Levels of dantrolene that inhibited the excitation- 
contraction coupling mechanism failed to suppress a halothane 
contracture in malignant hyperpyrexia muscle. Concentrations
of dantrolene that inhibited caffeine contractures in normal
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muscle completely suppressed halothane contractures in 
malignant hyperpyrexia muscle, lending support to a 
sarcoplasmic reticulum defect. Spontaneous contraction 
induced by the addition of potassium chloride and 
succinylcholine however imply that the sarcolemma is also 
affected.
The completeness of the relaxation and inhibition 
by dantrolene of halothane induced contractures in muscle 
from a susceptible patient supports its use in the treatment 
of malignant hyperpyrexia in vivo.
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SECTION IV - GENERAL DISCUSSION
The study presented in this thesis was undertaken 
to find the most suitable drug treatment for malignant 
hyperpyrexia. Methods employed included in vitro 
pharmacologic models of malignant hyperpyrexia based on 
normal human muscle. The efficacy of drugs suggested for 
the treatment of malignant hyperpyrexia was evaluated by 
measuring muscle response to drug administration in vitro. 
Muscle response to the drugs not only suggests a new drug 
treatment regime for malignant hyperpyrexia but also suggests 
specific biochemical changes in malignant hyperpyrexia 
muscle membranes. The aetiology of malignant hyperpyrexia 
appears to include the detailed molecular structure and 
association of the sarcoplasmic reticulum with the sarcolemma.
A: Membrane abnormalities in malignant hyperpyrexia muscle
Significant advances in membrane structure in recent 
years have led to a more sophisticated understanding of the 
structure and function of muscle cell membranes. The 
sarcolemma, its invaginations and the sarcoplasmic reticulum 
are excitable membranes.
Excitable membranes possess different levels of 
excitation or energisation. Phospholipid and its fluidity in 
a membrane play an important role in membrane function and 
probably in maintenance of the energised state (Luria, 1975; 
Tasaki, 1968) . If the level of excitation or energising level 
is increased, reaction to stimuli may be more easily induced.
Stimuli that do not normally induce a response in an 
excitable membrane may induce an effect if the level of 
excitation is increased high enough.
In recent years there have been significant advances 
in the understanding of the structure and function of the 
sarcoplasmic reticulum (calcium ATPase). In contrast, almost 
nothing is known about the calcium release mechanism.
The calcium ATPase actively pumps calcium from the 
myoplasm into the inside of the sarcoplasmic reticulum. If 
calcium is released from the sarcoplasmic reticulum and 
reaches a critical threshold level, contraction takes place 
by a relatively well understood mechanism (Murray and Weber, 
1974; Cohen, 1975).
The calcium ATPase of the sarcoplasmic reticulum 
keeps the concentration of calcium in the myoplasm so low 
that relaxation of the muscle is maintained. The mechanism 
of calcium release cannot be explained by a simple reversal 
of the pump. In fact, reversal can be induced in vitro but 
it is ten thousand times too slow to account for contraction 
in vivo. Ion channels in the SR membrane have been proposed 
for some time. A model with some form of activator mechanism 
is postulated to open the ion channels upon activation from 
the sarcolemma. Control of this process by an energised 
membrane and its phospholipid has been suggested (Lauria, 
1975).
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If fluidity of phospholipid can influence membrane
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activation, then the drugs studied in this thesis could be 
acting on muscle membranes by influencing the fluidity of the 
phospholipid. Any defect which maintains membranes in a 
super-fluid or abnormally high activated state, could result 
in impairment of membrane function. The sarcolemma appears 
to be a highly dynamic fluid controlled membrane with ion 
channels, and the sarcoplasmic reticulum a similar type of 
membrane but with different transport properties and energy 
states associated with it. The association between these two 
membranes is obviously critical to normal muscle function.
In the past, theories on membrane structure have had 
phospholipid evenly distributed around the surface of the 
membrane in the form of a bilayer (Danielli and Davson, 1935). 
That most membranes found in biology have various regions of 
phospholipid bilayers is now well established (Singer and 
Nicolson, 1972) . Recent work, using physical techniques on 
phospholipid model membranes and natural membranes has 
revealed a very dynamic organisation of difference types of 
phospholipid in membranes.
Membranes consist of various types of phospholipid. 
These different types of phospholipid in a pure state have 
different fluid properties. For example, artificial 
phosphatidylcholine membranes are more fluid than 
phosphatidylserine ones. Studies by Ohnishi and Ito (1974) 
and Ito and Ohnishi (1974) have conclusively demonstrated 
that in membranes with different phospholipids, specific types 
of phospholipid can be induced to aggregate. Thus, after 
aggregation there are solid and highly liquid regions or pores,
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and the process is reversible. The phenomenon is known as 
phase-separation and has now been shown to be induced by 
calcium (Ohnishi et al., 1974; Papahadjopoulos and Poste,
1975).
Phase-separation in excitable membranes provides a 
rational explanation for the development of the action 
potential in nerve, ionic transport across membranes and a 
molecular model of calcium induced calcium release in muscle 
cells (Ohnishi et al., 1974). Tasaki, Watanabe and Lerman 
(1967) showed that external calcium was essential for 
developing the action potential in the squid giant axon, 
whereas magnesium was completely ineffective. The ionic 
selectivity is remarkably parallel to that for inducing phase- 
separations in membranes containing phosphatidylserine. 
Moreover, Cook, Low and Ishijima (1972) showed involvement of 
phosphatidylserine in nerve excitation.
Protein, phospholipid chain length and the degree of 
unsaturation, sterol, inorganic ions and temperature have all 
been shown to alter phospholipid fluidity in membranes 
(Chapman and Wallach, 1973; Williams and Chapman, 1971;
Austin, Brown and Stewart, 1975). However, specific control 
mechanisms of phospholipid fluidity and the relative 
importance of interactions between some of these membrane 
components are not known. Calcium and magnesium have also 
been shown to reduce phospholipid fluidity or motion to 
differing degrees (Ohnishi et al., 1974). Thus, calcium/ 
magnesium ratios in membranes may play an important role in 
controlling fluidity. The effects of these ions on specific
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phospholipids are quite different. This affinity for 
specific phospholipids by calcium can induce phase separation 
within phospholipid membranes (Ito et al., 1974). The 
calcium-chelated ordered state and the disaggregated 
disordered state might be related to the two states in the 
theory of Tasaki (1968) on nerve excitation and the two 
membrane states in sarcoplasmic reticulum (Ohnishi et al.,
1974; Luria, 1975) .
Protein-phospholipid interaction is also thought to 
be important in controlling regions of phospholipid fluidity 
in excitable membranes (Austin et al., 1975; Brown, Bradbury, 
Austin and Stewart, 1975).
Energy is required to maintain the energised 
conformation of excitable membranes. If the supply of energy 
is uncoupled the membrane may be locked into the de-energised 
state. Cellular compensation by rapid hydrolysis of ATP may 
cause further depletion of energy reserves (Luria, 1975).
In summary, control of membrane fluidity has been 
suggested to be important in nerve and muscle membrane 
excitation or energy levels. Two states of lipid have been 
proposed, aggregated and diffuse with aggregated lipid being 
required for ionic flow across membranes. Halothane and most 
other general anaesthetics have a fluidising effect on normal 
membranes, increase intra-membrane bound calcium and sensitize 
the excitable membranes. It has been recently suggested that 
the sensitivity of an excitable membrane may depend on the 
fluidity of the phospholipids (Luria, 1975; Seeman, 1972).
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Thus, an excitable membrane is more easily triggered 
in vitro and the resultant muscle contracture is larger after 
treatment with halothane, because more calcium is available 
for release. A higher level of intra-membrane bound calcium 
would increase the likelihood of calcium induced phase 
separation in reticulum membranes.
The postulated halothane activation of the 
sarcolemma membrane would predict an increase in muscle 
response by external triggering agents. If normal human 
muscle is exposed to potassium chloride (80mM) in vitro no 
effect occurs, but if halothane is present causes a very sharp 
contracture (Moulds et al., 1974a). Thus, halothane has 
lowered the activation energy required to activate the 
sarcolemma membrane. The speed of recovery from the 
contracture suggests that the calcium ATPase pump is not 
affected (Moulds et al., 1974a; Nelson and Denborough, 1975, 
unpublished observations). Halothane also potentiates twitch 
response in normal human muscle, adding further support to the 
hypothesis (Nelson and Denborough, 1975, unpublished 
observations).
Halothane may increase the activation state of the 
sarcoplasmic reticulum as well as the sarcolemma. Caffeine at 
low concentrations in frog muscle (< 1 mM) and in human muscle 
(< 2 mM) does not cause contracture by itself but does appear 
to affect the sarcolemma membrane and the excitation- 
contraction coupling mechanism (Bianchi and Bolton, 1967; 
Nelson, Austin and Denborough, 1975, unpublished observations). 
Low concentrations of caffeine appear to modify membrane
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function by increasing the energy state of the membrane 
(Luttgau and Oetliker, 1968) . If halothane and caffeine 
are combined a super-activated state is produced, calcium is 
released and contracture occurs. Because the activation of 
the membranes is an artificial one however, the recovery is 
slow because the membranes remain highly activated while the 
halothane and caffeine are present. Caffeine effects can be 
reversed by simply replacing the muscle buffer. Pretreatment 
of normal muscle with low levels of caffeine renders the 
samples sensitive to the same agents that malignant 
hyperpyrexia muscle responds abnormally to in vitro. A 
lower mechanical threshold in malignant hyperpyrexia muscle 
membranes may explain the raised calcium levels in the 
myoplasm following treatment by one of the various triggering 
agents. The proposed increase in the excitation level of 
malignant hyperpyrexia muscle membranes also explains the 
abnormal in vitro responses to potassium chloride, 
succinylcholine, caffeine, halothane and an increase in 
temperature (Moulds and Denborough, 1974c).
The mode of action of local anaesthetics on 
membranes is variable and depends on many factors. The charge 
distribution of the anaesthetic, molecular weight, pH, 
temperature, the amount of cholesterol, ionic strength, 
anaesthetic concentration, calcium concentration, the nature 
of membrane lipids and levels of unsaturation, can all 
influence the anaesthetic membrane interaction (Seeman, 1972). 
These same factors have been shown to affect phospholipid 
fluidity in membranes (Chapman et al., 1973). Studies 
reviewed by Seeman (1972) and Papahadjopoulos (1972) strongly
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suggest that the action of local anaesthetics on membranes 
may be mediated via a specific interaction with acidic 
phospholipids.
Recent studies using Electron Spin Resonance 
techniques have shown that some local anaesthetics can induce 
significant molecular disordering and enhance the fluidity of 
phospholipids in natural and model membranes (Hubbell and 
McConnell, 1968; Hubbell, Metcalfe, Metcalfe and McConnell, 
1970; Trudell, Hubbell and Cohen, 1973; Butler, Schneider and 
Smith, 1973; Papahadjopoulos, Jacobson, Poste and Shepherd, 
1975). Very recent studies have shown that dibucaine 
increased the fluidity of acidic phospholipids and displaced 
calcium from membranes but had no effect on neutral 
phospholipid regions (Papahadjopoulos et al., 1975).
The apparent stimulation of calcium uptake into the 
sarcoplasmic reticulum may be based on the specific 
fluidizing effect of the local anaesthetics in regions of 
acidic phospholipids where ion pumps are located.
Cationic anaesthetics adsorb to the sarcoplasmic 
reticulum membrane preventing release of calcium and also 
displace sarcolemma bound calcium, blocking stimulus response 
coupling. Neutral anaesthetics have the opposite effect and 
increase the likelihood of calcium release from the reticulum. 
Such effects can be explained by the action of local 
anaesthetics on the phase-separation model of nerve 
excitation and calcium release from muscle membranes. 
Tetracaine acted antagonistically to the calcium induced phase
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separations described by Ohnishi (Ohnishi et al., 1974). The 
structure and mode of action of tetracaine is very similar to 
procaine (see figure 2). Local anaesthetics block the 
aggregation of phosphatidylserine molecules and thereby 
inhibit nerve impulses or calcium release from muscle 
membranes.
The molecular action of dexamethasone and 
hydrocortisone on muscle membranes is not known. The 
failure of dexamethasone to affect in vitro muscle 
contractures in normal or malignant hyperpyrexia muscle 
suggests that this drug is unable to affect muscle membranes. 
Although hydrocortisone inhibited and relaxed caffeine + 
halothane contractures in normal muscle, its effect on 
malignant hyperpyrexia muscle is unknown.
The postulation that dantrolene is an effective 
inhibitor of the abnormal response of malignant hyperpyrexia 
muscle in vitro by normalising phospholipid fluidity and/or 
membrane energisation levels has some indirect evidence in 
support of it.
In vitro testing of skeletal muscle from patients 
suffering from Dystrophia Myotonica have revealed several 
similarities to malignant hyperpyrexia muscle. Contractures 
were induced by potassium chloride and succinylcholine, but 
no abnormal response to caffeine could be demonstrated 
(Moulds and Denborough, 1974d; Moulds, 1974).
Evidence of abnormal cellular membranes other than
69
in muscle have been demonstrated for both myopathies. Roses, 
Butterfield, Appel and Chestnut (1975) and Butterfield, 
Chestnut, Roses and Appel (1974) have presented evidence that 
substantiates the presence of a membrane defect in myotonic 
erythrocytes. There was increased membrane fluidity and 
decreased polarity in myotonic membranes. Diphenylhydantoin 
(Phenytoin) normalized fluidity in myotonic membranes but had 
no effect on membranes from normal patients.
Diphenylhydantoin (see figure 2) has been demonstrated to be 
active at the membrane level and has been useful in the 
treatment of clinical myotonia. The implications from this 
study are important and the results represent one of the first 
properly documented membrane diseases in man attributable to 
phospholipid fluidity. Dantrolene is 1—{{{5— (4-nitrophenyl) 
-2-furanyl} methylene} amino} hydantoin (see figure 2) and has 
also been shown to be active at the membrane level. Its 
effect on phospholipid fluidity in muscle membranes is unknown 
and warrants further investigation. The evidence presented 
by Roses et al. (1975) that hydantoins affect phospholipid 
fluidity in human membranes suggests possible membrane 
interactions by dantrolene.
Temperature can be used to induce phase changes in 
sarcoplasmic reticulum (Inesi, Millman and Eletr, 1973).
Three states of membrane lipid-protein interaction were found 
in the temperature region of 20-40°C. Above 20°C the lipid 
matrix probed by spin labels exhibited a large increase in 
molecular motion and a decrease in the apparent ordering of 
lipid alkyl chains. In addition, labels covalently bound to 
enzyme reative sites indicated that the motion of protein side
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chains was sensitive to this transition.
Another modification, and perhaps the most important 
in relation to malignant hyperpyrexia, occured between 37°C 
and 40°C. At this temperature the processes of calcium 
accumulation and ATPase activity were uncoupled. Calcium 
accumulation was inhibited while calcium ATPase activity and 
passive calcium efflux proceeded at rapid rates. This process 
appears to be operational in malignant hyperpyrexia 
membranes.
Halothane does not induce a contracture in malignant 
hyperpyrexia muscle in vitro at 25°C but does illicit a 
response at 37°C. Halothane may increase the activation state 
of an abnormal membrane to the point where control of fluidity 
and protein-lipid interaction is lost.
An increase in temperature from about 22°C to 37°C 
is sufficient to induce contracture in malignant hyperpyrexia 
muscle in vitro (Moulds and Denborough, 1974b). The increase 
in body temperature during an episode of malignant 
hyperpyrexia would compound any loss of control over membrane 
fluidity.
Confirmation of the presence of an abnormal fluid 
state in malignant hyperpyrexia muscle membranes remains for 
future investigation. A study on the molecular interaction of 
dantrolene with membranes from normal and malignant 
hyperpyrexia muscle may shed some light on the molecular 
events during the onset of the syndrome.
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B: Clinical significance of the results
The results presented in this thesis suggest that 
dantrolene, hydrocortisone and procaine may inhibit or 
reverse malignant hyperpyrexia in humans.
Dexamethasone failed to produce any effect on in 
vitro muscle contracture. The failure of dexamethasone to 
affect halothane contractures in malignant hyperpyrexia muscle 
throws doubt on its suitability as a treatment for the 
syndrome. In a recent report, Isaacs showed that dexamethasone 
was not effective in preventing or reducing halothane-induced 
rigor in muscle from a susceptible patient (Isaacs, Heffron 
and Badenhorst, 1975). Thus, the suggested use of 
dexamethasone (Ellis, Clarke, Appleyard and Dinsdale, 1974) 
should be treated with reserve.
Pronestyl and procainamide were both less effective 
than procaine in antagonising muscle contracture, regardless 
of which in vitro model was used. The dose dependency of 
procaine suggests that the concentration required to produce 
a worthwhile effect is well above toxic levels for humans.
Over interpretation of results in this field of 
research is particularly noticeable. One report on the 
successful use of procaine in preventing malignant 
hyperpyrexia in swine caused considerable excitement at the 
time and prompted its use in humans (Harrison, 1971) . However 
the study reported that only two out of five pigs survived. 
These results were not able to be repeated in different strains
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of pigs (Hall, Trim and Woolf, 1972) and now some workers are 
suggesting the danger of its use outweighs any possible 
therapeutic value in humans (Hall et al., 1975).
Observations using normal muscle at high 
hydrocortisone concentrations imply that a very high clinical 
blood level of hydrocortisone is required for any effect to 
occur. High levels suppressed and relaxed caffeine + 
halothane contractures but not caffeine contractures. The 
relevance to treatment of malignant hyperpyrexia is therefore 
questionable and depends on which normal muscle model is 
selected as the most appropriate one. That hydrocortisone can 
be given in high clinical doses with little danger to the 
patient adds support to its use. Simultaneous use of 
hydrocortisone and procaine is possible. Both drugs were 
used in the treatment of malignant hyperpyrexia recently. The 
treatment was unsuccessful, however, and the patient died. The 
report failed to give dosage levels and drug therapy was begun 
very late in the development of the syndrome (Ryan and 
Appleyard, 1975).
The choice of dantrolene as an effective therapeutic 
agent in controlling malignant hyperpyrexia was confirmed by 
the in vitro study with muscle from a patient susceptible to 
malignant hyperpyrexia. The results presented in this thesis 
represent the first reported demonstration of the inhibiting 
effect of dantrolene on halothane induced muscle contracture 
in vitro with muscle from a susceptible patient. The fact 
that this drug completely suppressed halothane, potassium 
chloride, succinylcholine and caffeine contractures in
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malignant hyperpyrexia muscle, implies that dantrolene could 
be an effective therapeutic agent in vivo.
A significant contribution to the search for a 
suitable treatment regime for malignant hyperpyrexia was the 
successful use of dantrolene in controlling the porcine 
syndrome (Harrison, 1975). Relatively high concentrations 
were required however, and there is some doubt about the 
relationship between human and porcine malignant hyperpyrexia. 
Drugs should not be adopted therefore until proved effective 
with in vitro tests at clinical concentrations.
Blood levels required to reverse the syndrome in 
pigs were in excess of those found in humans after oral 
administration. The high doses given to pigs did not induce 
any major side effects (Harrison, 1975). Similarly high blood 
concentrations of dantrolene had no effect on dogs (Ellis, 
Simpson, Tatham, Leighton and Williams, 1975). The in vitro 
study described in this report suggests that lower 
concentrations of dantrolene, that have been measured in 
humans, may be equally effective in preventing or reversing 
malignant hyperpyrexia.
Dantrolene appears to be relatively safe when 
administered to humans, particularly at the clinical 
concentration used during this study. Although side effects 
have been reported following administration of dantrolene, 
they have all been minor.
The main side effects found following oral
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administration over a period of four weeks, with steady-state 
blood levels of about 6yM were general weakness, drowsiness, 
fatigue, dizziness, drunk feeling, headache and insomnia 
(Chyatte and Birdsong, 1971; Chyatte, Birdsong and Bergman, 
1971) .
Studies based on oral administration of dantrolene 
to humans imply that intravenous infusion at the 
concentrations suggested in this thesis, could be undertaken 
with safety. The speed of onset of the syndrome necessitates 
intravenous infusion for any drug to be effective.
Intravenous administration of dantrolene has yet to be 
approved in the United Kingdom or the United States of 
America. The drug is not available to Australian doctors for 
administration by any route.
No drug suggested for the treatment of malignant 
hyperpyrexia has proved reliable. The overwhelming efficacy 
of dantrolene in suppressing and reversing the abnormal 
contractures in muscle from susceptible patients, suggests 
dantrolene is the most suitable drug for the treatment of 
malignant hyperpyrexia. The safety of dantrolene should 
prompt authorities to approve parenteral administration. It 
would appear that dantrolene is the only drug tested so far, 
that could increase the appalling survival rate in malignant 
hyperpyrexia.
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APPENDIX - DATA ANALYSIS
One of the most important consequences of a study 
on muscle response, is the huge amount of data that is 
generated when compared to other methods of biochemical 
investigation. In the present study, eight different tests 
were devised to compare possible treatments for malignant 
hyperpyrexia. The six drugs that were tested resulted in 
over fifty (50) different types of experiment. Each 
experiment was repeated at least five times, with appropriate 
controls. Over eighty (80) normal subjects were selected 
and the biopsies performed resulted in approximately 600 
muscle fibres. Each fibre studied had an average of six 
tension readings. Every tension reading had concentration, 
treatment, and positional information associated with it. 
Fibres were also described by patient and buffer particulars, 
temperature, pH, weight and length as well as other factors. 
The total information in the present study amounted to over 
thirty-five thousand variables. A comprehensive computer 
system was therefore developed to handle the vast amount of 
data generated during this study.
The computation and analysis of the data was on 
three distinct levels. The first level comprised the 
conversion of chart divisions to tension in grams, via a 
program in FOCAL that ran on a PDP 8/1 computer. Preparing 
this data for analysis on a large computer, the University's 
UNIVAC 1108, then followed. A FORTRAN IV program assembled 
the data from the PDP 8/1 in addition to other information
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mentioned above, and then wrote the information on one of 
the system data files. System procedures on the UNIVAC 1108, 
under programer control, were then used to add the data 
file to the large data file which contained information about 
many experiments. This up-dating procedure comprised the 
second level of data analysis.
The third level of analysis involved interpretation, 
re-organisation, and statistical procedures on the data via 
a programing system called P-STAT. P-STAT is a computing 
system for file manipulation and statistical analysis of 
Science data originally developed in 1962 by a team of 
programers from the Princeton University computer centre 
(U.S.A.). P-STAT has been up-dated and revised almost 
annually since 1962 and is now implemented on over eight 
large scale computers.
A: Conversion of raw data
Fibre response was continually monitored by a 
Perkin-Elmer strip chart recorder. Changes in muscle tension 
were recorded as various peaks on the chart paper. Depending 
on the intensity of the response, four different settings of 
the amplifier attenuator and recorder would be selected as
follows:-
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Tension range
(g)
Amplifier attenuation 
(arbitrary units)
Recorder
(Volts full scale)
0 - 5 500 0.5
0 - 1 0 500 1.0
0 - 2 0 1000 1.0
0 - 4 0 2000 1.0
Settings would be changed during an experiment if 
the one selected before a treatment proved to be inappropriate. 
No contractures over 40 g were ever recorded.
The relationship of chart paper divisions to 
tension altered according to the range selected. A small 
program was written in FOCAL on a PDP 8/1 mini-computer to 
assist in converting the approximately 70 tension readings 
that were associated with each biopsy (figure 20).
The program resulted in a saving of time and an 
increase in accuracy, particularly if two biopsies were 
performed in one day. The computer terminal for the PDP 8/1 
was located adjacent to the laboratory and connected via 
telephone lines to the computer which was housed in the John 
Curtin School of Medical Research, a distance of about one 
mile.
The terminal was used to input:
1) the experiment number,
2) the voltage selected on the recorder,
3) the sensitivity of the amplifier,
4) a list of chart divisions for which corresponding 
figures were required.
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Program control was possible as data was input if a voltage 
or sensitivity setting had to be changed, the operator simply 
typed '11 and then the new settings. The program would then 
continue. If a mistake was made the operator typed a '99' 
which would automatically call an error routine. The error 
routine permitted any value that had been input previously 
to be corrected. Program control was returned to the exact 
position before the error was detected. Automatic print out 
of results would occur after every twenty-eight chart 
division values (one page of data). If less than 28 chart 
division conversions were required the operator typed 11* 
and then 'O' in reply to the voltage setting. A full 
summary of the data was then printed. The summary of the 
data included the peak number, tension in grams, the 
difference between tension figures, and chart divisions to 
enable easy checking of the results.
B: Tension figures added to the large data file
Tension data from the summaries printed by the 
FOCAL program were collected, added to other information 
describing the experiment and physically carried to the 
ANU computer centre. A program, 'UPDATE' written in Fortran 
IV and developed on the UNIVAC 1108, was then called (figures 
21, 21a). Data supplied to this program would be organised 
and then written to a data file. When a series of data files 
were collected describing a number of experiments, they were 
concentrated using UNIVAC 1108 system commands. The data 
file was saved on magnetic tape in case of system failure.
Figure 20
FOCAL program to convert chart divisions to tension (grams)
C-FOCAL, U01 
0 1.0 6 E
01.06 A “ANU“Z , !
01.1? A “ V " V ; IF ( V ) 1 . 1? , 5.05 ; A “S MS,!;IF ( 1 + A ( N + 1 ) ) 1 . 14,4 . 05 
01.14 IF ( 1-V ) 1 . 1? ,? . 10 ; S E3(N)«(A(N)*.05);R 4.05
02.10 IF (S-1 000 )2.50,2.80 :S B ( N ) = ( A ( N ) * . 4 ) ; G 4.05
02.50 8 B(N)-(A(N)*.1);G 4.05 
02,80 8 B(N)-(A(N)*.2)
04.05 8 N-N+1;IF (2°- N )5.05 , 5.05
04.10 IF (A(N+I-1)+9«)1.05,7.50
04 . 1? A A ( N )
04.16 IF (A(N)+H9)1.05,?.10:IF (-A(N ) ) 1 .14,1 . 14 : S N-N-1;G 1.1?
05.05 T ! ! ! ! ;IF (V ) 1 .12,5.20;8 N-N-1
05 .20 T “a NU“% 4 .0 ,Z ,! I
05.30 T “ NO . TEN ÜIFF DIV" !
05 .40 FOR I«1,1,N;D 6.0
05.60 Q
06.20 T %2.0,1,“ " ,%4.02,B(I),“
06.22 T % 4 .02,B (I )-B (I-1 ),“
06.25 T % 4 .0?,A(I) , !
07.10 A "N "I , !
07.20 T “« “A (N-I);A "C?“A (N-I)
07.30 8 N-N-IjG 1.12
07.50 S N-N+I-1;G 4.13 
*
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A terminal was used to input:
1. the experiment number, book and page number, date, year, 
muscle type, sex, temperature, buffer type and the pH of 
the buffer,
2. fibre number and length and weight of the fibre,
3. six comment codes which allowed a complete description 
of unusual experiments,
4. the peak number, concentration of a treatment, the 
treatment itself and the tension produced by the treatment.
All data from 1. was physically entered only once for each 
biopsy. The computer program however, described each fibre 
with this information as it was placed in the data file.
Program control was possible as data was entered. 
Error correction was possible by calling an error routine 
with a +99 for the peak number. A '-1' for the peak number 
would result in a question: "Finished, new fibre to be 
entered or totally new experiment?" A reply of'finished' 
would result in the data that had been entered being written 
to a data file, which was then put on a system 'SAVE' tape 
in case of system failure.
C: Statistical analysis of the large data file via P-STAT
on the UNIVAC 1108
After processes in the preceding section were 
complete, a large data file containing many thousands of 
pieces of information was available for analysis by 
appropriate programs. Because of the diverse array of 
questions that were to be asked, a general purpose program
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was required. The possibility of new questions arising after 
generation of the data necessitated a general program. The 
use of the P-STAT processing language was suggested by Mr. 
Bill Craig, Department of Clinical Science, John Curtin 
School of Medical Research.
P-STAT is a system of programs that does 
statistical operations on files of data. Version 3.06 1975, 
the system used to analyze data presented in this thesis, 
has 620 subroutines, totalling 55,000 FORTRAN source cards 
and 1,060 calls to various error routines.
It is a relatively easy language to use and is 
designed primarily for use by scientists and others who 
have neither the time nor the inclination to learn detailed 
computer programing.
The routine use of P-STAT was as follows:
1. The DATA program was called to provide an "english" 
version of the data file generated in section B.
2. The data in the "english" version was manually checked.
3. Mistakes found in the data file were corrected using the 
University of Maryland Editor on the UNIVAC 1108.
4. The DATA program was called again, this time to generate 
a permanent magnetic tape P-STAT version of the data.
5. P-STAT programs were written to select specific 
experiments that were required, and to provide standard 
statistical analysis of the data selected.
If more information was to be selected, a repeat
81
of Step 5 was all that was necessary. As data from new 
experiments became available, P-STAT would be used to 
generate a large P-STAT data file as follows:
6. Steps 1 - 4  above were repeated on the new data to be 
added to the large data file.
7. P-STAT was called to add the new data to the old large 
data file thus generating a new larger permanent P-STAT 
data file.
The P-STAT programs used to analyse the muscle 
data presented in this thesis, totalled over fifty separate 
programs. An example of a P-STAT program, used to select 
normal muscle fibres that were pre-treated with 6 yM 
dantrolene before the addition of 8 mM caffeine, is shown 
in figure 22.
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